Lamivudine and Tenofovir Disoproxil Fumarate Tablets

WARNINGS: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS AND POST TREATMENT EXACERBATIONS OF HEPATITIS B IN CO-INFECTED PATIENTS

See full prescribing information for complete boxed warning.

- Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine and tenofovir disoproxil fumarate. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. (5.1)
- Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine and tenofovir disoproxil fumarate. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment. (5.2)

-----INDICATIONS AND USAGE-----
Lamivudine and Tenofovir Disoproxil Fumarate Tablets, a combination of lamivudine and tenofovir disoproxil fumarate, both nucleoside analog HIV-1 reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. (1)

-----DOSAGE AND ADMINISTRATION-----
- Recommended dose: One tablet (containing 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate) once daily taken orally on an empty stomach. (2.1)

-----DOSAGE FORMS AND STRENGTHS-----
Tablets: 300 mg lamivudine and 300 mg tenofovir disoproxil fumarate. (3)

-----CONTRAINDICATIONS-----
Lamivudine and Tenofovir Tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the products. (4)

-----WARNINGS AND PRECAUTIONS-----
- Lactic acidosis and severe hepatomegaly with steatosis: Reported with the use of nucleoside analogues. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. (5.1)
- Severe acute exacerbations of hepatitis: Reported in patients who are co-infected with hepatitis B virus and HIV-1 and have discontinued lamivudine or tenofovir disoproxil fumarate. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment. (5.2)
- Co-infected HIV-1/HBV Patients: Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. (5.2)
- Coadministration with Other Products: Do not use with other lamivudine- or tenofovir-containing products or emtricitabine-containing products. Do not administer in combination with HEPESERA. (5.3)
- Hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving interferon and ribavirin-based regimens. Monitor for treatment-associated toxicities. Discontinue lamivudine and tenofovir disoproxil fumarate tablets, as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (5.4)
- Pancreatitis: Use with caution in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Discontinue lamivudine and tenofovir disoproxil fumarate tablets as clinically appropriate. (5.5)
- New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess creatinine clearance (CrCl) before initiating treatment with tenofovir disoproxil fumarate, a component of lamivudine and tenofovir disoproxil fumarate tablets. Monitor CrCl and serum phosphorus in patients at risk. Avoid administering lamivudine and tenofovir disoproxil fumarate with concurrent or recent use of nephrotoxic drugs. (5.6)
- Decreases in bone mineral density (BMD): Observed in HIV-infected patients. Consider assessment of BMD in patients with a history of pathologic fracture or other risk factors for osteoporosis or bone loss. (5.7)
- Immune reconstitution syndrome: Observed in HIV-infected patients. May necessitate further evaluation and treatment. (5.8)
- Redistribution/accumulation of body fat: Observed in HIV-infected patients receiving antiretroviral combination therapy. (5.9)
- Triple nucleoside-only regimens: Early virologic failure has been reported in HIV-infected patients. Monitor carefully and consider treatment modification. (5.10)

-----ADVERSE REACTIONS-----
- Most common adverse reactions are headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, rash, pain, depression, and cough. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----DRUG INTERACTIONS-----
- Zalcitabine is not recommended for use in combination with lamivudine and tenofovir disoproxil fumarate tablets. (7.2)
- Didanosine: Coadministration increases didanosine concentrations. Use with caution and monitor for evidence of didanosine toxicity (e.g., pancreatitis, neuropathy). Consider dose reductions or discontinuations of didanosine if warranted. (7.5)
- Atazanavir: Coadministration decreases atazanavir concentrations and increases tenofovir concentrations. Use atazanavir with lamivudine and tenofovir disoproxil fumarate only with additional ritonavir; monitor for evidence of tenofovir toxicity. (7.6)
- Lopinavir/ritonavir: Coadministration increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity. (7.7)

-----USE IN SPECIFIC POPULATIONS-----
- Nursing mothers: Women infected with HIV should be instructed not to breast feed. (8.3)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: August 2012
Lactic Acidosis and Severe Hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine, tenofovir disoproxil fumarate and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur [See Warnings and Precautions (5.1)].

Exacerbations of Hepatitis B: Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine and tenofovir disoproxil fumarate. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation anti-hepatitis B therapy may be warranted [See Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE
Lamivudine and tenofovir disoproxil fumarate tablets, a combination of lamivudine and tenofovir disoproxil fumarate, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 35 kg.

The following points should be considered when initiating therapy with lamivudine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection:
• Lamivudine and tenofovir disoproxil fumarate tablets should not be used in combination with ATRIPLA (efavirenz, emtricitabine, and tenofovir disoproxil fumarate), EMTRIVA (emtricitabine), TRUVADA (emtricitabine and tenofovir disoproxil fumarate), VIREAD (tenofovir disoproxil fumarate), HEPSERA (adefovir dipivoxil) or lamivudine-containing products including EPIVIR (lamivudine), EPIVIR-HBV (lamivudine), COMBIVIR (lamivudine/zidovudine), EPZICOM (abacavir sulfate and lamivudine), TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine) and COMPLERA (rilpivirine/emtricitabine/tenofovir) [See Warnings and Precautions (5.3)].

2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dose in Adults and Pediatric Patients >12 years of age and ≥35 kg
The dose of lamivudine and tenofovir disoproxil fumarate tablets containing 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate (equivalent to 245 mg of tenofovir disoproxil) is one tablet per day taken orally on an empty stomach.

2.2 Dose Adjustment for Renal Impairment
Because lamivudine and tenofovir disoproxil fumarate tablets are a fixed-dose combination tablet, it is not recommended for patients with impaired renal function (creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis.

3 DOSAGE FORMS AND STRENGTHS
Lamivudine and tenofovir disoproxil fumarate are for oral administration. Each tablet contains 300 mg lamivudine and 300 mg tenofovir disoproxil fumarate (which is equivalent to 245 mg of tenofovir disoproxil) as active ingredients.

4 CONTRAINDICATIONS
Lamivudine and Tenofovir Tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the products.

5 WARNINGS AND PRECAUTIONS
5.1 Lactic Acidosis/Severe Hepatomegaly With Steatosis
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including lamivudine and tenofovir disoproxil fumarate, components of lamivudine and tenofovir disoproxil fumarate tablets, in combination with other antiretrovirals. A majority of these cases have been in women. Obesity and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering nucleoside analogs to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with lamivudine and tenofovir disoproxil fumarate should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

5.2 Patients Coinfected with HIV-1 and HBV
Due to the risk of development of HIV-1 resistance, tenofovir disoproxil fumarate should only be used in HIV-1 and HBV coinfected patients as part of an appropriate antiretroviral combination regimen.
It is recommended that all patients with HIV-1 be tested for the presence of chronic hepatitis B before initiating treatment with tenofovir disoproxil fumarate.

Posttreatment Exacerbations of Hepatitis: In clinical trials in non-HIV-1-infected patients treated with lamivudine for chronic hepatitis B, clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of lamivudine. These exacerbations have been detected primarily by serum ALT elevations in addition to re-emergence of HBV DNA. Although most events appear to have been self-limited, fatalities have been reported in some cases. Similar events have been reported from postmarketing experience after changes from lamivudine-containing HIV-1 treatment regimens to non-lamivudine-containing regimens in patients infected with both HIV-1 and HBV. The causal relationship to discontinuation of lamivudine treatment is unknown. Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. There is insufficient evidence to determine whether re-initiation of lamivudine alters the course of posttreatment exacerbations of hepatitis.

Discontinuation of anti-HBV therapy, including lamivudine and tenofovir disoproxil fumarate, may be associated with severe acute exacerbations of hepatitis. Patients infected with HBV who discontinue lamivudine and tenofovir disoproxil fumarate should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Important Differences Among Lamivudine-Containing Products: Lamivudine Tablets contain a higher dose of the same active ingredient (lamivudine) than EPIVIR-HBV Tablets. EPIVIR-HBV was developed for patients with chronic hepatitis B. The formulation and dosage of lamivudine in EPIVIR-HBV are not appropriate for patients co-infected with HIV-1 and HBV. Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitis B in patients co-infected with HIV-1 and HBV. If treatment with EPIVIR-HBV or tenofovir disoproxil fumarate-containing product such as VIREAD is prescribed for chronic hepatitis B for a patient with unrecognized or untreated HIV-1 infection, rapid emergence of HIV-1 resistance is likely to result because of the subtherapeutic dose and the inappropriateness of monotherapy HIV-1 treatment.

Emergence of Lamivudine-Resistant HBV: In non-HIV-1-infected patients treated with lamivudine for chronic hepatitis B, emergence of lamivudine-resistant HBV has been detected and has been associated with diminished treatment response (see full prescribing information for EPIVIR-HBV for additional information). Emergence of hepatitis B virus variants associated with resistance to lamivudine has also been reported in HIV-1-infected patients who have received lamivudine-containing antiretroviral regimens in the presence of concurrent infection with hepatitis B virus.

5.3 Coadministration with Other Products
Lamivudine and tenofovir disoproxil fumarate tablet is a fixed dose combination product of lamivudine and tenofovir disoproxil fumarate. Lamivudine and tenofovir disoproxil fumarate should not be administered concomitantly with other lamivudine-containing, tenofovir disoproxil fumarate-containing or emtricitabine-containing drugs, including EPIVIR-HBV Tablets, Lamivudine Oral Solution, VIREAD (tenofovir disoproxil fumarate), COMBIVIR (lamivudine/zidovudine) Tablets, EPZICOM (abacavir sulfate and lamivudine) Tablets, or TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine), ATRIPLA® (efavirenz, emtricitabine, and tenofovir), EMTRIVA® (emtricitabine), TRUVADA® (emtricitabine and
Lamivudine and tenofovir disoproxil fumarate should not be administered in combination with HEPSERA (adefovir dipivoxil) [See Drug Interactions (7.8)].

5.4 Use With Interferon- and Ribavirin-Based Regimens
In vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as lamivudine, a component of lamivudine and tenofovir disoproxil fumarate tablets. Although no evidence of a pharmacokinetic or pharmacodynamic interaction (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine in HIV-1/HCV co-infected patients [see Clinical Pharmacology (12.3)], hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and lamivudine should be closely monitored for treatment-associated toxicities, especially hepatic decompensation. Discontinuation of lamivudine should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh >6). See the complete prescribing information for interferon and ribavirin.

5.5 Pancreatitis
In pediatric patients with a history of prior antiretroviral nucleoside exposure, a history of pancreatitis, or other significant risk factors for the development of pancreatitis, lamivudine, a component of lamivudine and tenofovir disoproxil fumarate tablets, should be used with caution. Treatment with lamivudine and tenofovir disoproxil fumarate tablets should be stopped immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur [see Adverse Reactions (6.1)].

5.6 New Onset or Worsening Renal Impairment
Tenofovir is principally eliminated by the kidney. Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir disoproxil fumarate, a component of lamivudine and tenofovir disoproxil fumarate tablets [See Adverse Reactions (6.2)]. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy and as clinically appropriate during therapy with tenofovir disoproxil fumarate, a component of lamivudine and tenofovir disoproxil fumarate tablets. Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients at risk for renal impairment, including patients who have previously experienced renal events while receiving HEPSERA®.

Dosing interval adjustment of tenofovir disoproxil fumarate and close monitoring of renal function are recommended in all patients with creatinine clearance below 50 mL/min. No safety or efficacy data are available in patients with renal impairment who received tenofovir disoproxil fumarate using these dosing guidelines, so the potential benefit of tenofovir disoproxil fumarate therapy should be assessed against the potential risk of renal toxicity.

Tenofovir disoproxil fumarate, a component of lamivudine and tenofovir disoproxil fumarate tablet should be avoided with concurrent or recent use of a nephrotoxic agent.
5.7 Decreases in Bone Mineral Density

Assessment of bone mineral density (BMD) should be considered for adults and pediatric patients 12 years of age and older who have a history of pathologic bone fracture or other risk factors for osteoporosis or bone loss. Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients. If bone abnormalities are suspected then appropriate consultation should be obtained.

In HIV-1 infected adult subjects treated with tenofovir disoproxil fumarate in Study 903 through 144 weeks, decreases from baseline in BMD were seen at the lumbar spine and hip in both arms of the trial. At Week 144, there was a significantly greater mean percentage decrease from baseline in BMD at the lumbar spine in subjects receiving tenofovir disoproxil fumarate + lamivudine + efavirenz (-2.2% ± 3.9) compared with subjects receiving stavudine + lamivudine + efavirenz (-1.0% ± 4.6). Changes in BMD at the hip were similar between the two treatment groups (-2.8% ± 3.5 in the tenofovir disoproxil fumarate group vs. -2.4% ± 4.5 in the stavudine group). In both groups, the majority of the reduction in BMD occurred in the first 24 to 48 weeks of the trial and this reduction was sustained through Week 144. Twenty-eight percent of tenofovir disoproxil fumarate-treated subjects vs. 21% of the stavudine-treated subjects lost at least 5% of BMD at the spine or 7% of BMD at the hip. Clinically relevant fractures (excluding fingers and toes) were reported in 4 subjects in the tenofovir disoproxil fumarate group and 6 subjects in the stavudine group. In addition, there were significant increases in biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C-telopeptide, and urinary N-telopeptide) in the tenofovir disoproxil fumarate group relative to the stavudine group, suggesting increased bone turnover. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in the tenofovir disoproxil fumarate group. Except for bone specific alkaline phosphatase, these changes resulted in values that remained within the normal range.

In clinical trials evaluating tenofovir disoproxil fumarate in HIV-1 infected pediatric subjects 2 to less than 18 years of age, bone effects were similar to those observed in adult subjects. Under normal circumstances BMD increases rapidly in pediatric patients. In Study 352 (2 to less than 12 years), the mean rate of BMD gain in lumbar spine at Week 48 was similar between the tenofovir disoproxil fumarate and the d4T or AZT treatment groups. Total body BMD gain was less in the tenofovir disoproxil fumarate compared to the d4T or AZT treatment group. One tenofovir disoproxil fumarate-treated subject and none of the d4T or AZT-treated subjects had significant loss (greater than 4%) of lumbar spine BMD at Week 48. Changes from baseline in BMD Z-scores were -0.012 for lumbar spine and -0.338 for total body in the 64 subjects who were treated with tenofovir disoproxil fumarate for 96 weeks. In Study 321 (12 to less than 18 years), the mean rate of BMD gain at Week 48 was less in the tenofovir disoproxil fumarate compared to the placebo treatment group. Six tenofovir disoproxil fumarate treated subjects and one placebo treated subject had significant (greater than 4%) lumbar spine BMD loss at Week 48. Changes from baseline BMD Z-scores were -0.341 for lumbar spine and -0.458 for total body in the 28 subjects who were treated with tenofovir disoproxil fumarate for 96 weeks. In both trials, skeletal growth (height) appeared to be unaffected. Markers of bone turnover in tenofovir disoproxil fumarate-treated pediatric subjects suggest increased bone turnover, consistent with the effects observed in adults.

The effects of tenofovir disoproxil fumarate-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown.
Cases of osteomalacia (associated with proximal renal tubulopathy and which may contribute to fractures) have been reported in association with the use of tenofovir disoproxil fumarate [See Adverse Reactions (6.2)].

The bone effects of tenofovir disoproxil fumarate have not been studied in patients with chronic HBV infection.

5.8 Immune Reconstitution Syndrome
Immune reconstitution syndrome has been reported in HIV-infected patients treated with combination antiretroviral therapy, including lamivudine and tenofovir disoproxil fumarate. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jirovecii* pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.

5.9 Fat Redistribution
In HIV-infected patients, redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving combination antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

5.10 Early Virologic Failure
Clinical trials in HIV-infected subjects have demonstrated that certain regimens that only contain three nucleoside reverse transcriptase inhibitors (NRTI) are generally less effective than triple drug regimens containing two NRTIs in combination with either a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor. In particular, early virological failure and high rates of resistance substitutions have been reported. Triple nucleoside regimens should therefore be used with caution. Patients on a therapy utilizing a triple nucleoside-only regimen should be carefully monitored and considered for treatment modification.

6 ADVERSE REACTIONS
The following adverse reactions are discussed in other sections of the labeling:

- Lactic Acidosis/Severe Hepatomegaly with Steatosis [See Boxed Warning, Warnings and Precautions (5.1)].
- Severe Acute Exacerbations of Hepatitis B [See Boxed Warning, Warnings and Precautions (5.2)].
- Hepatic decompensation in patients co-infected with HIV-1 and Hepatitis C [See Warnings and Precautions (5.4)].
- Pancreatitis [See Warnings and Precautions (5.5)].
- New Onset or Worsening Renal Impairment [See Warnings and Precautions (5.6)].
- Decreases in Bone Mineral Density [See Warnings and Precautions (5.7)].
- Immune Reconstitution Syndrome [See Warnings and Precautions (5.8)].
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Lamivudine
Adults - Clinical Trials in HIV-1: The safety profile of lamivudine in adults is primarily based on 3,568 HIV-1-infected patients in 7 clinical trials.

The most common adverse reactions are headache, nausea, malaise, fatigue, nasal signs and symptoms, diarrhea and cough.

Selected clinical adverse reactions in ≥5% of patients during therapy with Lamivudine 150 mg twice daily plus RETROVIR® 200 mg 3 times daily for up to 24 weeks are listed in Table 1.

Table 1 Selected Clinical Adverse Reactions (≥5% Frequency) in Four Controlled Clinical Trials (NUCA3001, NUCA3002, NUCB3001, NUCB3002)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Lamivudine 150 mg Twice Daily plus RETROVIR (n = 251)</th>
<th>RETROVIRa (n = 230)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a Whole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>35%</td>
<td>27%</td>
</tr>
<tr>
<td>Malaise &amp; fatigue</td>
<td>27%</td>
<td>23%</td>
</tr>
<tr>
<td>Fever or chills</td>
<td>10%</td>
<td>12%</td>
</tr>
<tr>
<td>Digestive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>33%</td>
<td>29%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>18%</td>
<td>22%</td>
</tr>
<tr>
<td>Nausea &amp; vomiting</td>
<td>13%</td>
<td>12%</td>
</tr>
<tr>
<td>Anorexia and/or decreased appetite</td>
<td>10%</td>
<td>7%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>9%</td>
<td>11%</td>
</tr>
<tr>
<td>Abdominal cramps</td>
<td>6%</td>
<td>3%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>5%</td>
<td>5%</td>
</tr>
<tr>
<td>Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropathy</td>
<td>12%</td>
<td>10%</td>
</tr>
<tr>
<td>Insomnia &amp; other sleep disorders</td>
<td>11%</td>
<td>7%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>10%</td>
<td>4%</td>
</tr>
<tr>
<td>Depressive disorders</td>
<td>9%</td>
<td>4%</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal signs &amp; symptoms</td>
<td>20%</td>
<td>11%</td>
</tr>
<tr>
<td>Cough</td>
<td>18%</td>
<td>13%</td>
</tr>
<tr>
<td>Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin rashes</td>
<td>9%</td>
<td>6%</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>12%</td>
<td>10%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>8%</td>
<td>6%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5%</td>
<td>5%</td>
</tr>
</tbody>
</table>

a Either zidovudine monotherapy or zidovudine in combination with zalcitabine.
Pancreatitis: Pancreatitis was observed in 9 of the 2,613 adult patients (0.3%) who received lamivudine in the controlled clinical trials EPV20001, NUCA3001, NUCB3001, NUCA3002, NUCB3002, and NUCB3007 [see Warnings and Precautions (5.5)].

Lamivudine 300 mg Once Daily: The types and frequencies of clinical adverse reactions reported in patients receiving lamivudine 300 mg once daily or lamivudine 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) for 48 weeks were similar.

Selected laboratory abnormalities observed during therapy are summarized in Table 2.

Table 2 Frequencies of Selected Grade 3-4 Laboratory Abnormalities in Adults in Four 24-Week Surrogate Endpoint Studies (NUCA3001, NUCA3002, NUCB3001, NUCB3002) and a Clinical Endpoint Study (NUCB3007)

<table>
<thead>
<tr>
<th>Test (Threshold Level)</th>
<th>24-Week Surrogate Endpoint Studiesa</th>
<th>Clinical Endpoint Studya</th>
<th>Placebo plus Current Therapyb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute neutrophil count (&lt;750/mm³)</td>
<td>7.2%</td>
<td>5.4%</td>
<td>15%</td>
</tr>
<tr>
<td>Hemoglobin (&lt;8.0 g/dL)</td>
<td>2.9%</td>
<td>1.8%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Platelets (&lt;50,000/mm³)</td>
<td>0.4%</td>
<td>1.3%</td>
<td>2.8%</td>
</tr>
<tr>
<td>ALT (&gt;5.0 x ULN)</td>
<td>3.7%</td>
<td>3.6%</td>
<td>3.8%</td>
</tr>
<tr>
<td>AST (&gt;5.0 x ULN)</td>
<td>1.7%</td>
<td>1.8%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Bilirubin (&gt;2.5 x ULN)</td>
<td>0.8%</td>
<td>0.4%</td>
<td>ND</td>
</tr>
<tr>
<td>Amylase (&gt;2.0 x ULN)</td>
<td>4.2%</td>
<td>1.5%</td>
<td>2.2%</td>
</tr>
</tbody>
</table>

a The median duration on study was 12 months.
b Either zidovudine monotherapy or zidovudine in combination with zalcitabine.
c Current therapy was either zidovudine, zidovudine plus didanosine, or zidovudine plus zalcitabine.

The frequencies of selected laboratory abnormalities reported in patients receiving lamivudine 300 mg once daily or lamivudine 150 mg twice daily (in 3-drug combination regimens in EPV20001 and EPV40001) were similar.

Pediatric Patients – Clinical Trials in HIV-1: Lamivudine Oral Solution has been studied in 638 pediatric patients 3 months to 18 years of age in 3 clinical trials.

Selected clinical adverse reactions and physical findings with a ≥5% frequency during therapy with lamivudine 4 mg/kg twice daily plus RETROVIR 160 mg/m² 3 times daily in therapy-naïve (≤56 days of antiretroviral therapy) pediatric patients are listed in Table 3.

Table 3 Selected Clinical Adverse Reactions and Physical Findings (≥5% Frequency) in Pediatric Patients in Study ACTG300
Adverse Reaction Lamivudine plus RETROVIR (n = 236) Didanosine (n = 235)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Lamivudine plus RETROVIR</th>
<th>Didanosine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body as a Whole</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>25%</td>
<td>32%</td>
</tr>
<tr>
<td><strong>Digestive</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatomegaly</td>
<td>11%</td>
<td>11%</td>
</tr>
<tr>
<td>Nausea &amp; vomiting</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>8%</td>
<td>6%</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>6%</td>
<td>12%</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>5%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>15%</td>
<td>18%</td>
</tr>
<tr>
<td>Abnormal breath sounds/wheezing</td>
<td>7%</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Ear, Nose, and Throat</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signs or symptoms of ears(^a)</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td>Nasal discharge or congestion</td>
<td>8%</td>
<td>11%</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin rashes</td>
<td>12%</td>
<td>14%</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>9%</td>
<td>11%</td>
</tr>
</tbody>
</table>

\(^a\) Includes pain, discharge, erythema, or swelling of an ear.

**Pancreatitis:** Pancreatitis, which has been fatal in some cases, has been observed in antiretroviral nucleoside-experienced pediatric patients receiving lamivudine alone or in combination with other antiretroviral agents. In an open-label dose-escalation study (NUCA2002), 14 patients (14%) developed pancreatitis while receiving monotherapy with lamivudine. Three of these patients died of complications of pancreatitis. In a second open-label study (NUCA2005), 12 patients (18%) developed pancreatitis. In Study ACTG300, pancreatitis was not observed in 236 patients randomized to lamivudine plus RETROVIR. Pancreatitis was observed in 1 patient in this study who received open-label lamivudine in combination with RETROVIR and ritonavir following discontinuation of didanosine monotherapy [see Warnings and Precautions (5.5)].

**Paresthesias and Peripheral Neuropathies:** Paresthesias and peripheral neuropathies were reported in 15 patients (15%) in Study NUCA2002, 6 patients (9%) in Study NUCA2005, and 2 patients (<1%) in Study ACTG300.

Selected laboratory abnormalities experienced by therapy-naive (≤56 days of antiretroviral therapy) pediatric patients are listed in Table 4.

**Table 4 Frequencies of Selected Grade 3-4 Laboratory Abnormalities in Pediatric Patients in Study ACTG300**
**Test (Threshold Level)** | **Lamivudine plus RETROVIR** | **Didanosine**
---|---|---
Absolute neutrophil count (<400/mm³) | 8% | 3%
Hemoglobin (<7.0 g/dL) | 4% | 2%
Platelets (<50,000/mm³) | 1% | 3%
ALT (>10 x ULN) | 1% | 3%
AST (>10 x ULN) | 2% | 4%
Lipase (>2.5 x ULN) | 3% | 3%
Total Amylase (>2.5 x ULN) | 3% | 3%

ULN = Upper limit of normal.

**Neonates - Clinical Trials in HIV-1:** Limited short-term safety information is available from 2 small, uncontrolled studies in South Africa in neonates receiving lamivudine with or without zidovudine for the first week of life following maternal treatment starting at Week 38 or 36 of gestation [see Clinical Pharmacology (12.3)]. Selected adverse reactions reported in these neonates included increased liver function tests, anemia, diarrhea, electrolyte disturbances, hypoglycemia, jaundice and hepatomegaly, rash, respiratory infections, and sepsis; 3 neonates died (1 from gastroenteritis with acidosis and convulsions, 1 from traumatic injury, and 1 from unknown causes). Two other nonfatal gastroenteritis or diarrhea cases were reported, including 1 with convulsions; 1 infant had transient renal insufficiency associated with dehydration. The absence of control groups limits assessments of causality, but it should be assumed that perinatally exposed infants may be at risk for adverse reactions comparable to those reported in pediatric and adult HIV-1-infected patients treated with lamivudine-containing combination regimens. Long-term effects of in utero and infant lamivudine exposure are not known.

**Tenofovir Disoproxil Fumarate**

**Clinical Trials in Adult Patients with HIV-1 Infection**

More than 12,000 subjects have been treated with tenofovir disoproxil fumarate alone or in combination with other antiretroviral medicinal products for periods of 28 days to 215 weeks in clinical trials and expanded access programs. A total of 1,544 subjects have received tenofovir disoproxil fumarate 300 mg once daily in clinical trials; over 11,000 subjects have received tenofovir disoproxil fumarate in expanded access programs.

The most common adverse reactions (incidence greater than or equal to 10%, Grades 2 to 4) identified from any of the 3 large controlled clinical trials include rash, diarrhea, headache, pain, depression, asthenia, and nausea.

**Treatment-Naïve Patients**

**Study 903 - Treatment-Emergent Adverse Reactions:** The most common adverse reactions seen in a double-blind comparative controlled trial in which 600 treatment-naïve subjects received tenofovir disoproxil fumarate (N=299) or stavudine (N=301) in combination with lamivudine and efavirenz for 144 weeks (Study 903) were mild to moderate gastrointestinal events and dizziness.

Mild adverse reactions (Grade 1) were common with a similar incidence in both arms, and included dizziness, diarrhea, and nausea. Selected treatment-emergent moderate to severe adverse reactions are summarized in Table 5.

**Table 5 Selected Treatment-Emergent Adverse Reactions**

(Grades 2 to 4) Reported in
### 5% in Any Treatment Group in Study 903 (0 to 144 Weeks)

<table>
<thead>
<tr>
<th></th>
<th>Tenofovir disoproxil fumarate + 3TC + EFV</th>
<th>d4T + 3TC + EFV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=299</td>
<td>N=301</td>
</tr>
<tr>
<td><strong>Body as a Whole</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>14%</td>
<td>17%</td>
</tr>
<tr>
<td>Pain</td>
<td>13%</td>
<td>12%</td>
</tr>
<tr>
<td>Fever</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>7%</td>
<td>12%</td>
</tr>
<tr>
<td>Back pain</td>
<td>9%</td>
<td>8%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>6%</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Digestive System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11%</td>
<td>13%</td>
</tr>
<tr>
<td>Nausea</td>
<td>8%</td>
<td>9%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>4%</td>
<td>5%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>5%</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Metabolic Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipodystrophy(^b)</td>
<td>1%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5%</td>
<td>7%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td><strong>Nervous System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>11%</td>
<td>10%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>5%</td>
<td>8%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3%</td>
<td>6%</td>
</tr>
<tr>
<td>Peripheral neuropathy(^c)</td>
<td>1%</td>
<td>5%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>6%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>5%</td>
<td>5%</td>
</tr>
<tr>
<td><strong>Skin and Appendages</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash event(^d)</td>
<td>18%</td>
<td>12%</td>
</tr>
</tbody>
</table>

\(^a\) Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.

\(^b\) Lipodystrophy represents a variety of investigator-described adverse events not a protocol-defined syndrome.

\(^c\) Peripheral neuropathy includes peripheral neuritis and neuropathy.

\(^d\) Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash.

**Laboratory Abnormalities:** With the exception of fasting cholesterol and fasting triglyceride elevations that were more common in the stavudine group (40% and 9%) compared with tenofovir disoproxil fumarate (19% and 1%) respectively, laboratory abnormalities observed in this trial occurred with similar frequency in the tenofovir disoproxil fumarate and stavudine treatment arms. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 6.

**Table 6 Grade 3/4 Laboratory Abnormalities Reported in 1% of Tenofovir Disoproxil Fumarate-Treated Subjects in Study 903 (0–144 Weeks)**
Tenofovir disoproxil fumarate + 3TC + EFV  
N=299  
Fasting Cholesterol (>240 mg/dL) 19% 40%  
Creatine Kinase (M: >990 U/L; F: >845 U/L) 12% 12%  
Serum Amylase (>175 U/L) 9% 8%  
AST (M: >180 U/L; F: >170 U/L) 5% 7%  
ALT (M: >215 U/L; F: >170 U/L) 4% 5%  
Hematuria (>100 RBC/HPF) 7% 7%  
Neutrophils (<750/mm³) 3% 1%  
Fasting Triglycerides (>750 mg/dL) 1% 9%  

Any Grade 3 Laboratory Abnormality 36% 42%  
Fasting Cholesterol (>240 mg/dL) 19% 40%  
Creatine Kinase (M: >990 U/L; F: >845 U/L) 12% 12%  
Serum Amylase (>175 U/L) 9% 8%  
AST (M: >180 U/L; F: >170 U/L) 5% 7%  
ALT (M: >215 U/L; F: >170 U/L) 4% 5%  
Hematuria (>100 RBC/HPF) 7% 7%  
Neutrophils (<750/mm³) 3% 1%  
Fasting Triglycerides (>750 mg/dL) 1% 9%  

Study 934 - Treatment Emergent Adverse Reactions: In Study 934, 511 antiretroviral-naïve subjects received either tenofovir disoproxil fumarate + EMTRIVA® administered in combination with efavirenz (N=257) or zidovudine/lamivudine administered in combination with efavirenz (N=254). Adverse reactions observed in this trial were generally consistent with those seen in previous studies in treatment-experienced or treatment-naïve subjects (Table 7).

Table 7 Selected Treatment-Emergent Adverse Reactionsa (Grades 2 to 4) Reported in 5% in Any Treatment Group in Study 934 (0 to 144 Weeks)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Tenofovir disoproxil fumarateb + FTC + EFV</th>
<th>d4T + 3TC + EFV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=257</td>
<td>N=254</td>
</tr>
<tr>
<td><strong>Gastrointestinal Disorder</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>9%</td>
<td>5%</td>
</tr>
<tr>
<td>Nausea</td>
<td>9%</td>
<td>7%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td><strong>General Disorders and Administration Site Condition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>9%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Infections and Infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinusitis</td>
<td>8%</td>
<td>4%</td>
</tr>
<tr>
<td>Upper respiratory tract infections</td>
<td>8%</td>
<td>5%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>5%</td>
<td>3%</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>6%</td>
<td>5%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Psychiatric Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>9%</td>
<td>7%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>5%</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Skin and Subcutaneous Tissue Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash eventc</td>
<td>7%</td>
<td>9%</td>
</tr>
</tbody>
</table>

a Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.
b From Weeks 96 to 144 of the trial, subjects received TRUVADA with efavirenz in place of
tenofovir disoproxil fumarate + EMTRIVA with efavirenz.

Rash event includes rash, exfoliative rash, rash generalized, rash macular, rash maculopapular, rash pruritic, and rash vesicular.

Laboratory Abnormalities: Laboratory abnormalities observed in this trial were generally consistent with those seen in previous trials (Table 8).

Table 8 Significant Laboratory Abnormalities Reported in 1% of Subjects in Any Treatment Group in Study 934 (0 to 144 Weeks)

<table>
<thead>
<tr>
<th>Laboratory Abnormality</th>
<th>Tenofovir disoproxil fumarate + FTC + EFV</th>
<th>AZT/3TC + EFV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any Grade 3 Laboratory Abnormality</td>
<td>30%</td>
<td>26%</td>
</tr>
<tr>
<td>Fasting Cholesterol (&gt;240 mg/dL)</td>
<td>22%</td>
<td>24%</td>
</tr>
<tr>
<td>Creatine Kinase (M: &gt;990 U/L; F: &gt;845 U/L)</td>
<td>9%</td>
<td>7%</td>
</tr>
<tr>
<td>Serum Amylase (&gt;175 U/L)</td>
<td>8%</td>
<td>4%</td>
</tr>
<tr>
<td>Alkaline Phosphatase (&gt;550 U/L)</td>
<td>1%</td>
<td>0%</td>
</tr>
<tr>
<td>AST (M: &gt;180 U/L; F: &gt;170 U/L)</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>ALT (M: &gt;215 U/L; F: &gt;170 U/L)</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td>Hemoglobin (&lt;8.0 mg/dL)</td>
<td>0%</td>
<td>4%</td>
</tr>
<tr>
<td>Hyperglycemia (&gt;250 mg/dL)</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Hematuria (&gt;75 RBC/HPF)</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Glycosuria (3+)</td>
<td>&lt;1%</td>
<td>1%</td>
</tr>
<tr>
<td>Neutrophils (&lt;750/mm³)</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td>Fasting Triglycerides (&gt;750 mg/dL)</td>
<td>4%</td>
<td>2%</td>
</tr>
</tbody>
</table>

- From Weeks 96 to 144 of the trial, subjects received TRUVADA with efavirenz in place of tenofovir disoproxil fumarate + EMTRIVA with efavirenz.

Treatment-Experienced Patients

Treatment-Emergent Adverse Reactions: The adverse reactions seen in treatment experienced subjects were generally consistent with those seen in treatment naïve subjects including mild to moderate gastrointestinal events, such as nausea, diarrhea, vomiting, and flatulence. Less than 1% of subjects discontinued participation in the clinical trials due to gastrointestinal adverse reactions (Study 907).

A summary of moderate to severe, treatment-emergent adverse reactions that occurred during the first 48 weeks of Study 907 is provided in Table 9.

Table 9 Selected Treatment-Emergent Adverse Reactions (Grades 2 to 4) Reported in 3% in Any Treatment Group in Study 907 (0 to 48 Weeks)

<table>
<thead>
<tr>
<th></th>
<th>Tenofovir disoproxil fumarate (N=368) (Week 0 to 24)</th>
<th>Placebo (N=182) (Week 0 to 24)</th>
<th>Tenofovir disoproxil fumarate (N=368) (Week 0 to 48)</th>
<th>Placebo Crossover to Tenofovir disoproxil fumarate (N=170) (Week 24 to 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a Whole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>TDF</td>
<td>PL</td>
<td>TDF</td>
<td>PL</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------</td>
<td>--------</td>
<td>-------</td>
<td>--------</td>
</tr>
<tr>
<td>Asthenia</td>
<td>7%</td>
<td>6%</td>
<td>11%</td>
<td>1%</td>
</tr>
<tr>
<td>Pain</td>
<td>7%</td>
<td>7%</td>
<td>12%</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>5%</td>
<td>5%</td>
<td>8%</td>
<td>2%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>4%</td>
<td>3%</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td>Back pain</td>
<td>3%</td>
<td>3%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>Chest pain</td>
<td>3%</td>
<td>1%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Fever</td>
<td>2%</td>
<td>2%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>Digestive System</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11%</td>
<td>10%</td>
<td>16%</td>
<td>11%</td>
</tr>
<tr>
<td>Nausea</td>
<td>8%</td>
<td>5%</td>
<td>11%</td>
<td>7%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4%</td>
<td>1%</td>
<td>7%</td>
<td>5%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>3%</td>
<td>2%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>3%</td>
<td>2%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>Flatulence</td>
<td>3%</td>
<td>1%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>2%</td>
<td>0%</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Nervous System</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>4%</td>
<td>3%</td>
<td>8%</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>3%</td>
<td>2%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>3%</td>
<td>3%</td>
<td>5%</td>
<td>2%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1%</td>
<td>3%</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Skin and Appendage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash event</td>
<td>5%</td>
<td>4%</td>
<td>7%</td>
<td>1%</td>
</tr>
<tr>
<td>Sweating</td>
<td>3%</td>
<td>2%</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>3%</td>
<td>3%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>Metabolic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight loss</td>
<td>2%</td>
<td>1%</td>
<td>4%</td>
<td>2%</td>
</tr>
</tbody>
</table>

a. Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.
b. Peripheral neuropathy includes peripheral neuritis and neuropathy.
c. Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash.

Laboratory Abnormalities: Laboratory abnormalities observed in this trial occurred with similar frequency in the tenofovir disoproxil fumarate and placebo-treated groups. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 10.

**Table 10 Grade 3/4 Laboratory Abnormalities Reported in 1% of Tenofovir Disoproxil Fumarate-Treated Subjects in Study 907 (0 to 48 Weeks)**
Clinical Trials in Pediatric Subjects 2 Years of Age and Older with HIV-1 Infection
Assessment of adverse reactions is based on two randomized trials (Study 352 and 321) in 184 HIV-1 infected pediatric subjects (2 to less than 18 years of age) who received treatment with tenofovir disoproxil fumarate (N=93) or placebo/active comparator (N=91) in combination with other antiretroviral agents for 48 weeks. The adverse reactions observed in subjects who received treatment with tenofovir disoproxil fumarate were consistent with those observed in clinical trials in adults.

Bone effects observed in pediatric subjects 2 years of age and older were consistent with those observed in adult clinical trials [See Warnings and Precautions (5.7)].

Eighty-nine pediatric subjects received tenofovir disoproxil fumarate in Study 352 (48 who were initially randomized to tenofovir disoproxil fumarate and 41 who were initially randomized to continue stavudine or zidovudine and then received tenofovir disoproxil fumarate in the extension phase) for a median exposure of 104 weeks. Of these, 4 subjects discontinued from the trial due to adverse reactions consistent with proximal renal tubulopathy. Three of these 4 subjects presented with hypophosphatemia and also had decreases in total body or spine BMD Z score [See Warnings and Precautions (5.7)].

6.2 Postmarketing Experience
In addition to adverse reactions reported from clinical trials, the following adverse reactions have been reported during postmarketing use of lamivudine and tenofovir disoproxil fumarate. Because these reactions are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to lamivudine and tenofovir disoproxil fumarate.

Lamivudine
Body as a Whole: Redistribution/accumulation of body fat [see Warnings and Precautions
Endocrine and Metabolic: Hyperglycemia.
General: Weakness.
Hemic and Lymphatic: Anemia (including pure red cell aplasia and severe anemias progressing on therapy).
Hepatic and Pancreatic: Lactic acidosis and hepatic steatosi s, posttreatment exacerbation of hepatitis B [see Boxed Warning, Warnings and Precautions (5.1, 5.2)].
Hypersensitivity: Anaphylaxis, urticaria.
Musculoskeletal: Muscle weakness, CPK elevation, rhabdomyolysis.
Skin: Alopecia, pruritus.

Tenofovir Disoproxil Fumarate
Immune System Disorders: Allergic reaction, including angioedema
Metabolism and Nutrition Disorders: Lactic acidosis, hypokalemia, hypophosphatemia
Respiratory, Thoracic, and Mediastinal Disorders: Dyspnea
Gastrointestinal Disorders: Pancreatitis, increased amylase, abdominal pain
Hepatobiliary Disorders: Hepatic steatosis, hepatitis, increased liver enzymes (most commonly AST, ALT gamma GT)
Skin and Subcutaneous Tissue Disorders: Rash
Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to fractures), muscular weakness, myopathy
Renal and Urinary Disorders: Acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria
General Disorders and Administration Site Conditions: Asthenia

The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia, hypokalemia, muscular weakness, myopathy, hypophosphatemia.

7 DRUG INTERACTIONS
No drug interaction studies have been conducted using lamivudine and tenofovir disoproxil fumarate tablets. Drug interaction studies have been conducted with lamivudine and tenofovir disoproxil fumarate, the components of lamivudine and tenofovir disoproxil fumarate tablets [see Clinical Pharmacology (12.3)].

Lamivudine
Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim). No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.

7.1 Interferon- and Ribavirin-Based Regimens
Although no evidence of a pharmacokinetic or pharmacodynamic interaction (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine in HIV-1/HCV co-infected patients, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin [see Warnings and Precautions (5.4),
7.2 Zalcitabine
Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another. Therefore, use of lamivudine and tenofovir disoproxil fumarate tablets in combination with zalcitabine is not recommended.

7.3 Trimethoprim/Sulfamethoxazole (TMP/SMX)
No change in dose of either drug is recommended. There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat PCP.

7.4 Drugs with No Observed Interactions with Lamivudine
A drug interaction study showed no clinically significant interaction between lamivudine and zidovudine.

Tenofovir Disoproxil Fumarate

7.5 Didanosine
Coadministration of tenofovir disoproxil fumarate and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse reactions. Didanosine should be discontinued in patients who develop didanosine-associated adverse reactions.

When administered with tenofovir disoproxil fumarate, the C$_{max}$ and AUC of didanosine (administered as either the buffered or enteric-coated formulation) increased significantly [See Clinical Pharmacology (12.3)]. The mechanism of this interaction is unknown. Higher didanosine concentrations could potentiate didanosine-associated adverse reactions, including pancreatitis, and neuropathy. Suppression of CD4$^+$ cell counts has been observed in patients receiving tenofovir disoproxil fumarate (tenofovir DF) with didanosine 400 mg daily.

In patients weighing greater than 60 kg, the didanosine dose should be reduced to 250 mg when it is coadministered with tenofovir disoproxil fumarate. Data are not available to recommend a dose adjustment of didanosine for adults or pediatric patients weighing less than 60 kg. When coadministered, tenofovir disoproxil fumarate and didanosine EC may be taken under fasted conditions or with a light meal (less than 400 kcal, 20% fat). Coadministration of didanosine buffered tablet formulation with tenofovir disoproxil fumarate should be under fasted conditions.

7.6 Atazanavir
Atazanavir has been shown to increase tenofovir concentrations [See Clinical Pharmacology (12.3)]. The mechanism of this interaction is unknown. Patients receiving atazanavir and tenofovir disoproxil fumarate should be monitored for tenofovir disoproxil fumarate-associated adverse reactions. Tenofovir Disoproxil Fumarate should be discontinued in patients who develop tenofovir disoproxil fumarate-associated adverse reactions.

Tenofovir Disoproxil Fumarate decreases the AUC and C$_{min}$ of atazanavir [See Clinical Pharmacology (12.3)]. When coadministered with tenofovir disoproxil fumarate, it is recommended that atazanavir 300 mg is given with ritonavir 100 mg. Atazanavir without ritonavir should not be coadministered with tenofovir disoproxil fumarate.
7.7 Lopinavir/Ritonavir
Lopinavir/ritonavir has been shown to increase tenofovir concentrations [See Clinical Pharmacology (12.3)]. The mechanism of this interaction is unknown. Patients receiving lopinavir/ritonavir and tenofovir disoproxil fumarate should be monitored for tenofovir disoproxil fumarate-associated adverse reactions. Tenofovir Disoproxil Fumarate should be discontinued in patients who develop tenofovir disoproxil fumarate-associated adverse reactions.

7.8 Drugs Affecting Renal Function
Since tenofovir is primarily eliminated by the kidneys [See Clinical Pharmacology (12.3)], coadministration of tenofovir disoproxil fumarate with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of tenofovir and/or increase the concentrations of other renally eliminated drugs. Some examples include, but are not limited to cidofovir, acyclovir, valacyclovir, ganciclovir, and valganciclovir. Drugs that decrease renal function may also increase serum concentrations of tenofovir.

In the treatment of chronic hepatitis B, tenofovir disoproxil fumarate should not be administered in combination with HEPSERA (adefovir dipivoxil).

8 USE IN SPECIFIC POPULATION
8.1 Pregnancy
Lamivudine is classified under category C. Tenofovir disoproxil fumarate is classified under category B. There are no adequate and well-controlled studies of the combination of lamivudine and tenofovir disoproxil fumarate in pregnant women. Lamivudine and tenofovir disoproxil fumarate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lamivudine: Animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. Increased early embryolethality occurred in rabbits at exposure levels similar to those in humans.

Lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in South Africa. The study assessed pharmacokinetics in: 16 women at 36 weeks gestation using 150 mg lamivudine twice daily with zidovudine, 10 women at 38 weeks gestation using 150 mg lamivudine twice daily with zidovudine, and 10 women at 38 weeks gestation using lamivudine 300 mg twice daily without other antiretrovirals. These studies were not designed or powered to provide efficacy information. Lamivudine pharmacokinetics in pregnant women were similar to those seen in non-pregnant adults and in postpartum women. Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples. In a subset of subjects, lamivudine amniotic fluid specimens were collected following natural rupture of membranes. Amniotic fluid concentrations of lamivudine were typically 2 times greater than maternal serum levels and ranged from 1.2 to 2.5 mcg/mL (150 mg twice daily) and 2.1 to 5.2 mcg/mL (300 mg twice daily). It is not known whether risks of adverse events associated with lamivudine are altered in pregnant women compared with other HIV-1-infected patients.

Animal reproduction studies performed at oral doses up to 130 and 60 times the adult dose in rats and rabbits, respectively, revealed no evidence of teratogenicity due to lamivudine. Increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. However, there was no indication of this effect in rats at exposure levels up to 35
times those in humans. Based on animal studies, lamivudine crosses the placenta and is transferred to the fetus [see Nonclinical Toxicology (13.2)].

**Tenofovir Disoproxil Fumarate:** Reproduction studies have been performed in rats and rabbits at doses up to 14 and 19 times the human dose based on body surface area comparisons and revealed no evidence of impaired fertility or harm to the fetus due to tenofovir. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, tenofovir disoproxil fumarate should be used during pregnancy only if clearly needed.

**8.3 Nursing Mothers**
The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. Because of both the potential for HIV-1 transmission and serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving lamivudine and tenofovir disoproxil fumarate.

**Lamivudine:** Lamivudine is excreted into human milk. Samples of breast milk obtained from 20 mothers receiving lamivudine monotherapy (300 mg twice daily) or combination therapy (150 mg lamivudine twice daily and 300 mg zidovudine twice daily) had measurable concentrations of lamivudine.

**Tenofovir Disoproxil Fumarate:** Studies in rats have demonstrated that tenofovir is secreted in milk. In humans, samples of breast milk obtained from five HIV-1 infected mothers in the first post-partum week show that tenofovir is excreted in human milk at low levels. The impact of this exposure in breastfed infants is unknown.

**8.4 Pediatric Use**
Lamivudine and tenofovir disoproxil fumarate tablets are not recommended in patients less than 12 years of age weighing less than 35 kg (77 lb) because it is a fixed dose combination formulation containing a component, tenofovir disoproxil fumarate, for which safety and efficacy have not been established in this age group.

**8.5 Geriatric Use**
Clinical studies of lamivudine and tenofovir disoproxil fumarate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for the elderly patient should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

**8.6 Patients with impaired renal function**
Lamivudine and tenofovir disoproxil fumarate tablets are not recommended for patients with impaired renal function (i.e., creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis because it is a fixed-dose combination formulation that cannot be adjusted.

**10 OVERDOSAGE**
If overdose occurs the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.
Lamivudine: There is no known antidote for lamivudine. One case of an adult ingesting 6 grams of lamivudine was reported; there were no clinical signs or symptoms noted and hematologic tests remained normal. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event. If overdose occurs, the patient should be monitored, and standard supportive treatment applied as required.

Tenofovir Disoproxil Fumarate: Limited clinical experience at doses higher than the therapeutic dose of tenofovir disoproxil fumarate 300 mg is available. In Study 901, 600 mg tenofovir disoproxil fumarate was administered to 8 subjects orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.

Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of tenofovir disoproxil fumarate, a four-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.

11 DESCRIPTION
Lamivudine and tenofovir disoproxil fumarate tablets are fixed dose combination tablets containing lamivudine and tenofovir disoproxil fumarate for oral administration. The tablets are capsule shaped bilayered, biconvex, film-coated tablets with one layer orange and other layer white in color, “LT” debossed on one side and plain on the other side. Each tablet contains 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate (which is equivalent to 245 mg of tenofovir disoproxil) as active ingredients. The tablets include the following inactive ingredients: Microcrystalline Cellulose, Lactose Monohydrate, Sodium Starch Glycolate, Corn Starch, Croscarmellose Sodium, Magnesium Stearate, Polysorbate 80, FD&C Yellow No 6 (Aluminium Lake), Opadry AMBOY-B-29000 Translucent (Polyvinyl alcohol- Part. Hydrolyzed, Talc, Lecithin (soya), Xanthan Gum).

Lamivudine is a synthetic nucleoside analogue with activity against HIV-1 and HBV. Tenofovir disoproxil fumarate (a prodrug of tenofovir) which is a fumaric acid salt of bis-isopropoxycarbonyloxy methyl ester derivative of tenofovir. In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5’-monophosphate. Tenofovir exhibits activity against HIV-1 reverse transcriptase.

Lamivudine: The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2',3'-dideoxy, 3'-thiacytidine. It has a molecular formula of C₈H₁₁N₃O₃S and a molecular weight of 229.3. It has the following structural formula:
Lamivudine is a white to off-white crystalline solid with a solubility of approximately 70 mg/mL in water at 20°C.

Tenofovir Disoproxil Fumarate: The chemical name of tenofovir disoproxil fumarate is 9-[(R)-2-[[bis[[isopropoxycarbonyl]oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C₁₉H₃₀N₅O₁₀P • C₄H₄O₄ and a molecular weight of 635.52. It has the following structural formula:

![Structural formula of Tenofovir Disoproxil Fumarate]

12 CLINICAL PHARMACOLOGY
For additional information on Mechanism of Action, Antiviral Activity, Resistance and Cross Resistance, please consult the lamivudine and tenofovir disoproxil fumarate prescribing information.

12.1 Mechanism of Action
Lamivudine and Tenofovir Disoproxil Fumarate Tablets are a fixed dose combination of antiviral drugs lamivudine and tenofovir disoproxil fumarate [see Clinical Pharmacology (12.4)].

12.3 Pharmacokinetics
Pharmacokinetics in Adults
Lamivudine and tenofovir disoproxil fumarate from the combination tablets (300 mg/300 mg) were bioequivalent to that from EPIVIR Tablets and VIREAD Tablets respectively, when administered to healthy volunteers under fasting conditions.

Lamivudine
The pharmacokinetic properties of lamivudine have been studied in asymptomatic, HIV-1-infected adult patients after administration of single intravenous (IV) doses ranging from 0.25 to 8 mg/kg, as well as single and multiple (twice-daily regimen) oral doses ranging from 0.25 to 10 mg/kg.

The pharmacokinetic properties of lamivudine have also been studied as single and multiple oral doses ranging from 5 mg to 600 mg/day administered to HBV-infected patients.

The steady-state pharmacokinetics properties of the lamivudine 300-mg tablet once daily for 7 days compared with the lamivudine 150-mg tablet twice daily for 7 days were assessed in a crossover study in 60 healthy volunteers. Lamivudine 300 mg once daily resulted in lamivudine exposures that were similar to lamivudine 150 mg twice daily with respect to plasma AUC₂₄,₆₆, however, Cₘₐₓ,₆₆ was 66% higher and the trough value was 53% lower compared with the 150-mg twice-daily regimen. Intracellular lamivudine triphosphate
exposures in peripheral blood mononuclear cells were also similar with respect to AUC_{24,ss} and C_{max,24,ss}; however, trough values were lower compared with the 150-mg twice-daily regimen. Inter-subject variability was greater for intracellular lamivudine triphosphate concentrations versus lamivudine plasma trough concentrations. The clinical significance of observed differences for both plasma lamivudine concentrations and intracellular lamivudine triphosphate concentrations is not known.

Absorption and Bioavailability: Lamivudine was rapidly absorbed after oral administration in HIV-1-infected patients. Absolute bioavailability in 12 adult patients was 86% ± 16% (mean ± SD) for the 150-mg tablet and 87% ± 13% for the oral solution. After oral administration of 2 mg/kg twice a day to 9 adults with HIV-1, the peak serum lamivudine concentration (C_{max}) was 1.5 ± 0.5 mcg/mL (mean ± SD). The area under the plasma concentration versus time curve (AUC) and C_{max} increased in proportion to oral dose over the range from 0.25 to 10 mg/kg.

The accumulation ratio of lamivudine in HIV-1-positive asymptomatic adults with normal renal function was 1.50 following 15 days of oral administration of 2 mg/kg twice daily.

Effects of Food on Oral Absorption: An investigational 25-mg dosage form of lamivudine was administered orally to 12 asymptomatic, HIV-1-infected patients on 2 occasions, once in the fasted state and once with food (1,099 kcal; 75 grams fat, 34 grams protein, 72 grams carbohydrate). Absorption of lamivudine was slower in the fed state (T_{max}: 3.2 ± 1.3 hours) compared with the fasted state (T_{max}: 0.9 ± 0.3 hours); C_{max} in the fed state was 40% ± 23% (mean ± SD) lower than in the fasted state. There was no significant difference in systemic exposure (AUC_{ss}) in the fed and fasted states; therefore, lamivudine tablets may be administered with or without food.

Distribution: The apparent volume of distribution after IV administration of lamivudine to 20 patients was 1.3 ± 0.4 L/kg, suggesting that lamivudine distributes into extravascular spaces. Volume of distribution was independent of dose and did not correlate with body weight.

Binding of lamivudine to human plasma proteins is low (<36%). In vitro studies showed that over the concentration range of 0.1 to 100 mcg/mL, the amount of lamivudine associated with erythrocytes ranged from 53% to 57% and was independent of concentration.

Metabolism: Metabolism of lamivudine is a minor route of elimination. In man, the only known metabolite of lamivudine is the trans-sulfoxide metabolite. Within 12 hours after a single oral dose of lamivudine in 6 HIV-l-infected adults, 5.2% ± 1.4% (mean ± SD) of the dose was excreted as the trans-sulfoxide metabolite in the urine. Serum concentrations of this metabolite have not been determined.

Elimination: The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion. In 9 healthy subjects given a single 300-mg oral dose of lamivudine, renal clearance was 199.7 ± 56.9 mL/min (mean ± SD). In 20 HIV-l-infected patients given a single IV dose, renal clearance was 280.4 ± 75.2 mL/min (mean ± SD), representing 71% ± 16% (mean ± SD) of total clearance of lamivudine.

In most single-dose studies in HIV-1-infected patients, HBV-infected patients, or healthy subjects with serum sampling for 24 hours after dosing, the observed mean elimination half-
life ($t_{1/2}$) ranged from 5 to 7 hours. In HIV-1-infected patients, total clearance was $398.5 \pm 69.1$ mL/min (mean $\pm$ SD). Oral clearance and elimination half-life were independent of dose and body weight over an oral dosing range from 0.25 to 10 mg/kg.

**Tenofovir Disoproxil Fumarate**

The pharmacokinetics of tenofovir disoproxil fumarate have been evaluated in healthy volunteers and HIV-1 infected individuals. Tenofovir pharmacokinetics are similar between these populations.

**Absorption:** Tenofovir disoproxil fumarate is a water soluble diester prodrug of the active ingredient tenofovir. The oral bioavailability of tenofovir from tenofovir disoproxil fumarate in fasted subjects is approximately 25%. Following oral administration of a single dose of tenofovir disoproxil fumarate 300 mg to HIV-1 infected subjects in the fasted state, maximum serum concentrations ($C_{\text{max}}$) are achieved in $1.0 \pm 0.4$ hrs. $C_{\text{max}}$ and AUC values are $0.30 \pm 0.09 \mu g/mL$ and $2.29 \pm 0.69 \mu g \cdot hr/mL$, respectively.

The pharmacokinetics of tenofovir are dose proportional over a tenofovir disoproxil fumarate dose range of 75 to 600 mg and are not affected by repeated dosing.

**Distribution:** In vitro binding of tenofovir to human plasma or serum proteins is less than 0.7 and 7.2%, respectively, over the tenofovir concentration range $0.01$ to $25 \mu g/mL$. The volume of distribution at steady-state is $1.3 \pm 0.6$ L/kg and $1.2 \pm 0.4$ L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.

**Metabolism and Elimination:** In vitro studies indicate that neither tenofovir disoproxil nor tenofovir are substrates of CYP enzymes.

Following IV administration of tenofovir, approximately 70–80% of the dose is recovered in the urine as unchanged tenofovir within 72 hours of dosing. Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours. After multiple oral doses of tenofovir disoproxil fumarate 300 mg once daily (under fed conditions), 32 $\pm$ 10% of the administered dose is recovered in urine over 24 hours.

Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion. There may be competition for elimination with other compounds that are also renally eliminated.

**Effects of Food on Oral Absorption:** Administration of tenofovir disoproxil fumarate following a high-fat meal (~700 to 1000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir $AUC_{0-\infty}$ of approximately 40% and an increase in $C_{\text{max}}$ of approximately 14%. However, administration of tenofovir disoproxil fumarate with a light meal did not have a significant effect on the pharmacokinetics of tenofovir when compared to fasted administration of the drug. Food delays the time to tenofovir $C_{\text{max}}$ by approximately 1 hour. $C_{\text{max}}$ and AUC of tenofovir are $0.33 \pm 0.12 \mu g/mL$ and $3.32 \pm 1.37 \mu g \cdot hr/mL$ following multiple doses of tenofovir disoproxil fumarate 300 mg once daily in the fed state, when meal content was not controlled.

**Effect of Food on Absorption of Lamivudine and Tenofovir Disoproxil Fumarate Tablets:** The
effect of food on lamivudine and tenofovir disoproxil fumarate tablets was not determined; therefore, this product must be administered on an empty stomach.

**Special Populations**

**Race**

*Lamivudine:* There are no significant racial differences in lamivudine pharmacokinetics.

*Tenofovir Disoproxil Fumarate:* There were insufficient numbers from racial and ethnic groups other than Caucasian to adequately determine potential pharmacokinetic differences among these populations.

**Pediatric Patients:**

*Lamivudine:* In Study NUCA2002, pharmacokinetic properties of lamivudine were assessed in a subset of 57 HIV-1-infected pediatric patients (age range: 4.8 months to 16 years, weight range: 5 to 66 kg) after oral and IV administration of 1, 2, 4, 8, 12, and 20 mg/kg/day. In the 9 infants and children (range: 5 months to 12 years of age) receiving oral solution 4 mg/kg twice daily (the usual recommended pediatric dose), absolute bioavailability was 66% ± 26% (mean ± SD), which was less than the 86% ± 16% (mean ± SD) observed in adults. The mechanism for the diminished absolute bioavailability of lamivudine in infants and children is unknown.

Systemic clearance decreased with increasing age in pediatric patients, as shown in Figure 1.

**Figure 1. Systemic Clearance (L/hr•kg) of Lamivudine in Relation to Age**

After oral administration of lamivudine 4 mg/kg twice daily to 11 pediatric patients ranging from 4 months to 14 years of age, $C_{\text{max}}$ was 1.1 ± 0.6 mcg/mL and half-life was 2.0 ± 0.6 hours. (In adults with similar blood sampling, the half-life was 3.7 ± 1 hours.) Total exposure to lamivudine, as reflected by mean AUC values, was comparable between pediatric patients receiving an 8-mg/kg/day dose and adults receiving a 4-mg/kg/day dose.

Distribution of lamivudine into cerebrospinal fluid (CSF) was assessed in 38 pediatric patients after multiple oral dosing with lamivudine. CSF samples were collected between 2 and 4 hours postdose. At the dose of 8 mg/kg/day, CSF lamivudine concentrations in 8 patients ranged from 5.6% to 30.9% (mean ± SD of 14.2% ± 7.9%) of the concentration in a
simultaneous serum sample, with CSF lamivudine concentrations ranging from 0.04 to 0.3 mcg/mL.

Limited, uncontrolled pharmacokinetic and safety data are available from administration of lamivudine (and zidovudine) to 36 infants up to 1 week of age in 2 studies in South Africa. In these studies, lamivudine clearance was substantially reduced in 1-week-old neonates relative to pediatric patients (>3 months of age) studied previously. There is insufficient information to establish the time course of changes in clearance between the immediate neonatal period and the age-ranges >3 months old [see Adverse Reactions (6.1)].

**Tenofovir Disoproxil Fumarate:**

**Pediatric Patients 2 Years of Age and Older:** Steady-state pharmacokinetics of tenofovir were evaluated in 31 HIV-1 infected pediatric subjects 2 to less than 18 years (Table 11). Tenofovir exposure achieved in these pediatric subjects receiving oral once daily doses of tenofovir disoproxil fumarate 300 mg (tablet) or 8 mg/kg of body weight (powder) up to a maximum dose of 300 mg was similar to exposures achieved in adults receiving once-daily doses of tenofovir disoproxil fumarate 300 mg.

**Table 11 Mean (± SD) Tenofovir Pharmacokinetic Parameters by Age Groups for Pediatric Patients**

<table>
<thead>
<tr>
<th>Dose and Formulation</th>
<th>300 mg Tablet</th>
<th>8 mg/kg Oral Powder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12 to &lt;18 Year (N=8)</td>
<td>2 to &lt;12 Years (N=23)</td>
</tr>
<tr>
<td>C_{max} (μg/mL)</td>
<td>0.38 ± 0.13</td>
<td>0.24 ± 0.13</td>
</tr>
<tr>
<td>AUC_{tot} (μg•hr/mL)</td>
<td>3.39 ± 1.22</td>
<td>2.59 ± 1.06</td>
</tr>
</tbody>
</table>

**Geriatric Patients:** The pharmacokinetics of lamivudine and tenofovir disoproxil fumarate have not been studied in patients over 65 years of age.

**Gender: Lamivudine and Tenofovir Disoproxil Fumarate:** There are no significant gender differences in lamivudine pharmacokinetics.

**Patients with Impaired Renal Function:** See Use in Specific Populations (8.6).

Lamivudine and Tenofovir Disoproxil Fumarate Tablets are not recommended for patients with impaired renal function (i.e., creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis because it is a fixed-dose combination formulation that cannot be adjusted.

**Patients with Hepatic Impairment:**

**Lamivudine:** The pharmacokinetic properties of lamivudine have been determined in adults with impaired hepatic function. Pharmacokinetic parameters were not altered by diminishing hepatic function; therefore, no dose adjustment for lamivudine is required for patients with impaired hepatic function. Safety and efficacy of lamivudine have not been established in the presence of decompensate liver disease.

**Tenofovir disoproxil fumarate:** The pharmacokinetics of tenofovir following a 300 mg single dose of tenofovir disoproxil fumarate have been studied in non-HIV infected subjects with moderate to severe hepatic impairment. There were no substantial alterations in tenofovir pharmacokinetics in subjects with hepatic impairment compared with unimpaired subjects.
No change in tenofovir disoproxil fumarate dosing is required in patients with hepatic impairment.

Assessment of Drug Interactions: See Drug Interactions (7).

No drug interaction studies have been conducted using lamivudine and tenofovir disoproxil fumarate tablets.

Lamivudine:

Interferon Alfa: There was no significant pharmacokinetic interaction between lamivudine and interferon alfa in a study of 19 healthy male subjects [see Warnings and Precautions (5.4)].

Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].

Trimethoprim/Sulfamethoxazole: Lamivudine and TMP/SMX were coadministered to 14 HIV-1-positive patients in a single-center, open-label, randomized, crossover study. Each patient received treatment with a single 300 mg dose of lamivudine and TMP 160 mg/SMX 800 mg once a day for 5 days with concomitant administration of lamivudine 300 mg with the fifth dose in a crossover design. Coadministration of TMP/SMX with lamivudine resulted in an increase of 43% ± 23% (mean ± SD) in lamivudine AUC∞, a decrease of 29% ± 13% in lamivudine oral clearance, and a decrease of 30% ± 36% in lamivudine renal clearance. The pharmacokinetic properties of TMP and SMX were not altered by coadministration with lamivudine [see Drug Interactions (7.3)].

Zidovudine: No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12 asymptomatic HIV-1-infected adult patients given a single dose of zidovudine (200 mg) in combination with multiple doses of lamivudine (300 mg q 12 hr) [see Drug Interactions (7.4)].

Tenofovir Disoproxil Fumarate:

At concentrations substantially higher (~300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP3A4, CYP2D6, CYP2C9, or CYP2E1. However, a small (6%) but statistically significant reduction in metabolism of CYP1A substrate was observed. Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP mediated interactions involving tenofovir disoproxil fumarate with other medicinal products is low [see Clinical Pharmacology (12.3)].

Tenofovir Disoproxil Fumarate has been evaluated in healthy volunteers in combination with abacavir, atazanavir, didanosine, efavirenz, emtricitabine, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral contraceptives, ribavirin, saquinavir/ritonavir, and tacrolimus. Tables 12 and 13 summarize pharmacokinetic effects of coadministered drug on tenofovir pharmacokinetics and effects of tenofovir disoproxil fumarate on the pharmacokinetics of coadministered drug.
Table 12: Drug Interactions: Changes in Pharmacokinetic Parameters for Tenofovir in the Presence of the Coadministered Drug

<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>Dose of Coadministered Drug (mg)</th>
<th>N</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (90% CI)</th>
<th>AUC (90% CI)</th>
<th>C&lt;sub&gt;min&lt;/sub&gt; (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abacavir</td>
<td>300 once daily</td>
<td>8</td>
<td>⇔</td>
<td>⇔</td>
<td>NC</td>
</tr>
<tr>
<td>Atazanavir&lt;sup&gt;c&lt;/sup&gt;</td>
<td>400 once daily x 14 days</td>
<td>33</td>
<td>↑ 14 (↑ 8 to ↑ 20)</td>
<td>↑ 24 (↑ 21 to ↑ 28)</td>
<td>↑ 22 (↑ 15 to ↑ 30)</td>
</tr>
<tr>
<td>Didanosine (enteric-coated)</td>
<td>400 once</td>
<td>25</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Didanosine (buffered)</td>
<td>250 or 400 once daily x 7 days</td>
<td>14</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>600 once daily x 14 days</td>
<td>29</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Emtricitabine</td>
<td>200 once daily x 7 days</td>
<td>17</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Entecavir</td>
<td>1 mg once daily x 10 days</td>
<td>28</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Indinavir</td>
<td>800 three times daily x 7 days</td>
<td>13</td>
<td>↑ 14 (↓ 3 to ↑ 33)</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>150 twice daily x 7 days</td>
<td>15</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Lopinavir/Ritonavir</td>
<td>400/100 twice daily x 14 days</td>
<td>24</td>
<td>⇔</td>
<td>↑ 32 (↑ 25 to ↑ 38)</td>
<td>↑ 51 (↑ 37 to ↑ 66)</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>1250 twice daily x 14 days</td>
<td>29</td>
<td>⇔</td>
<td>⇔</td>
<td>⇔</td>
</tr>
<tr>
<td>Saquinavir/Ritonavir</td>
<td>1000/100 twice daily x 14 days</td>
<td>35</td>
<td>⇔</td>
<td>⇔</td>
<td>↑ 23 (↑ 16 to ↑ 30)</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>0.05 mg/kg twice daily x 7 days</td>
<td>21</td>
<td>↑ 13 (↑ 1 to ↑ 27)</td>
<td>⇔</td>
<td>⇔</td>
</tr>
</tbody>
</table>

<sup>a</sup> Subjects received tenofovir disoproxil fumarate 300 mg once daily.
<sup>b</sup> Increase = ↑; Decrease = ↓; No Effect = ⇔; NC = Not Calculated
<sup>c</sup> Reyataz (atazanavir) Prescribing Information

Following multiple dosing to HIV-1 and HBV-negative subjects receiving either chronic methadone maintenance therapy or oral contraceptives, or single doses of ribavirin, steady-state tenofovir pharmacokinetics were similar to those observed in previous trials, indicating lack of clinically significant drug interactions between these agents and tenofovir disoproxil fumarate.

---

Table 13: Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Tenofovir Disoproxil Fumarate
<table>
<thead>
<tr>
<th>Coadministered Drug</th>
<th>Dose of Coadministered Drug (mg)</th>
<th>N</th>
<th>% Change of Coadministered Drug Pharmacokinetic Parameters&lt;sup&gt;a&lt;/sup&gt; (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>C&lt;sub&gt;max&lt;/sub&gt;</strong></td>
</tr>
<tr>
<td>Abacavir</td>
<td>300 once</td>
<td>8</td>
<td>↑ 12 (↓ 1 to ↑ 26)</td>
</tr>
<tr>
<td>Atazanavir&lt;sup&gt;b&lt;/sup&gt;</td>
<td>400 once daily × 14 days</td>
<td>34</td>
<td>↓ 21 (↓ 27 to ↓ 14)</td>
</tr>
<tr>
<td></td>
<td>Atazanavir/Ritonavir 300/100 once daily × 42 days</td>
<td>10</td>
<td>↓ 28 (↓ 50 to ↑ 5)</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>600 once daily × 14 days</td>
<td>30</td>
<td>⇐</td>
</tr>
<tr>
<td>Emtricitabine</td>
<td>200 once daily × 7 days</td>
<td>17</td>
<td>⇐</td>
</tr>
<tr>
<td>Entecavir</td>
<td>1 mg once daily × 10 days</td>
<td>28</td>
<td>⇐</td>
</tr>
<tr>
<td>Indinavir</td>
<td>800 three times daily × 7 days</td>
<td>12</td>
<td>↓ 11 (↓ 30 to ↑ 12)</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>150 twice daily × 7 days</td>
<td>15</td>
<td>↓ 24 (↓ 34 to ↓ 12)</td>
</tr>
<tr>
<td>Lopinavir/Ritonavir</td>
<td>Lopinavir/Ritonavir 400/100 twice daily × 14 days</td>
<td>24</td>
<td>⇐</td>
</tr>
<tr>
<td>Methadone&lt;sup&gt;d&lt;/sup&gt;</td>
<td>40 to 110 once daily × 14 days&lt;sup&gt;e&lt;/sup&gt;</td>
<td>13</td>
<td>⇐</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>1250 twice daily × 14 days</td>
<td>29</td>
<td>⇐</td>
</tr>
<tr>
<td>M8 metabolite</td>
<td>Ethinyl Estradiol/Norgestimate (Ortho-Tricyclen) once daily × 7 days</td>
<td>20</td>
<td>⇐</td>
</tr>
<tr>
<td>Oral Contraceptives&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Ethinyl Estradiol/Norgestimate (Ortho-Tricyclen) once daily × 7 days</td>
<td>20</td>
<td>⇐</td>
</tr>
<tr>
<td>Ribavirin</td>
<td>600 once</td>
<td>22</td>
<td>⇐</td>
</tr>
<tr>
<td>Saquinavir/Ritonavir</td>
<td>Saquinavir/Ritonavir 1000/100 twice daily × 14 days</td>
<td>32</td>
<td>↑ 22 (↑ 6 to ↑ 41)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Pharmacokinetic parameters: C<sub>max</sub> (maximal concentration), AUC (area under the curve), C<sub>min</sub> (minimal concentration).<br><br><sup>b</sup> Atazanavir is coadministered with ritonavir.<br><br><sup>c</sup> C<sub>max</sub> and C<sub>min</sub> values are provided for comparison purposes only and do not represent actual changes in pharmacokinetic parameters.<br><br><sup>d</sup> Methadone is coadministered with activated charcoal.<br><br><sup>e</sup> Co-administration duration: 14 days.<br><br><sup>f</sup> Oral contraceptives are coadministered with the study drug regimen.<br><br><sup>g</sup> Changes in C<sub>max</sub> and C<sub>min</sub> are calculated based on % increases or decreases from baseline.
In HIV-infected subjects, addition of tenofovir DF to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and C\textsubscript{min} values of atazanavir that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.

R-(active), S- and total methadone exposures were equivalent when dosed alone or with tenofovir disoproxil fumarate.

Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported.

Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with tenofovir disoproxil fumarate.

Increases in AUC and C\textsubscript{min} are not expected to be clinically relevant; hence no dose adjustments are required when tenofovir DF and ritonavir-boosted saquinavir are coadministered.

Table 14 summarizes the drug interaction between tenofovir disoproxil fumarate and didanosine. Coadministration of tenofovir disoproxil fumarate and didanosine should be undertaken with caution [See Drug Interactions (7.5)]. When administered with multiple doses of tenofovir disoproxil fumarate, the C\textsubscript{max} and AUC of didanosine 400 mg increased significantly. The mechanism of this interaction is unknown. When didanosine 250 mg enteric-coated capsules were administered with tenofovir disoproxil fumarate, systemic exposures to didanosine were similar to those seen with the 400 mg enteric-coated capsules alone under fasted conditions.

<table>
<thead>
<tr>
<th>Didanosine Dose (mg)/Method of Administration</th>
<th>Tenofovir Disoproxil Fumarate Method of Administration\textsuperscript{a}</th>
<th>N</th>
<th>% Difference (90% CI) vs. Didanosine 400 mg Alone, Fasted\textsuperscript{b}</th>
<th>C\textsubscript{max}</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Buffered tablets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>400 once daily\textsuperscript{c} × 7 days</td>
<td>Fasted 1 hour after didanosine</td>
<td>14</td>
<td>↑ 28 (↑ 11 to ↑ 48)</td>
<td>↑ 44 (↑ 31 to ↑ 59)</td>
<td></td>
</tr>
<tr>
<td><strong>Enteric coated capsules</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>400 once, fasted</td>
<td>With food, 2 hours after didanosine</td>
<td>26</td>
<td>↑ 48 (↑ 25 to ↑ 76)</td>
<td>↑ 48 (↑ 31 to ↑ 67)</td>
<td></td>
</tr>
<tr>
<td>400 once, with food</td>
<td>Simultaneously with didanosine</td>
<td>26</td>
<td>↑ 64 (↑ 41 to ↑ 89)</td>
<td>↑ 60 (↑ 44 to ↑ 79)</td>
<td></td>
</tr>
<tr>
<td>250 once, fasted</td>
<td>With food, 2 hours after didanosine</td>
<td>28</td>
<td>↓ 10 (↓ 22 to ↑ 3)</td>
<td>⇝</td>
<td></td>
</tr>
<tr>
<td>250 once, fasted</td>
<td>Simultaneously with didanosine</td>
<td>28</td>
<td>⇝</td>
<td>↑ 14 (0 to ↑ 31)</td>
<td></td>
</tr>
<tr>
<td>250 once, with food</td>
<td>Simultaneously with didanosine</td>
<td>28</td>
<td>↓ 29 (↓ 39 to ↓ 18)</td>
<td>↓ 11 (↓ 23 to ↑ 2)</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a} Administration with food was with a light meal (~373 kcal, 20% fat).

\textsuperscript{b} Increase = ↑; Decrease = ↓; No Effect = ⇝

\textsuperscript{c} Includes 4 subjects weighing <60 kg receiving ddI 250 mg.
12.4 Microbiology

Mechanism of Action

*Lamivudine:* Intracellularly, lamivudine is phosphorylated to its active 5’-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue into viral DNA. 3TC-TP is a weak inhibitor of mammalian DNA polymerases α, β, and γ.

*Tenofovir Disoproxil Fumarate:* Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil fumarate requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate, an obligate chain terminator. Tenofovir diphosphate inhibits the activity of HIV-1 reverse transcriptase and HBV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.

Antiviral Activity

*Lamivudine:* The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood lymphocytes) using standard susceptibility assays. EC₅₀ values (50% effective concentrations) were in the range of 0.003 to 15 μM (1 μM = 0.23 mcg/mL). HIV-1 from therapy-naive subjects with no amino acid substitutions associated with resistance gave median EC₅₀ values of 0.429 μM (range: 0.200 to 2.007 μM) from Virco (n = 92 baseline samples from COLA40263) and 2.35 μM (1.37 to 3.68 μM) from Monogram Biosciences (n = 135 baseline samples from ESS30009). The EC₅₀ values of lamivudine against different HIV-1 clades (A-G) ranged from 0.001 to 0.120 μM, and against HIV-2 isolates from 0.003 to 0.120 μM in peripheral blood mononuclear cells. Ribavirin (50 μM) decreased the anti-HIV-1 activity of lamivudine by 3.5 fold in MT-4 cells. In HIV-1-infected MT-4 cells, lamivudine in combination with zidovudine at various ratios exhibited synergistic antiretroviral activity. Please see the full prescribing information for EPIVIR-HBV for information regarding the inhibitory activity of lamivudine against HBV.

*Tenofovir Disoproxil Fumarate:* The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes. The EC₅₀ (50% effective concentration) values for tenofovir were in the range of 0.04 μM to 8.5 μM. In drug combination studies of tenofovir with nucleoside reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, zalcitabine, zidovudine), non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz, nevirapine), and protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), additive to synergistic effects were observed. Tenofovir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC₅₀ values ranged from 0.5 μM to 2.2 μM) and strain specific activity against HIV-2 (EC₅₀ values ranged from 1.6 μM to 5.5 μM).

Resistance

*Lamivudine:* Lamivudine-resistant variants of HIV-1 have been selected in cell culture. Genotypic analysis showed that the resistance was due to a specific amino acid substitution in
the HIV-1 reverse transcriptase at codon 184 changing the methionine to either isoleucine or valine (M184V/I).

HIV-1 strains resistant to both lamivudine and zidovudine have been isolated from patients. Susceptibility of clinical isolates to lamivudine and zidovudine was monitored in controlled clinical trials. In patients receiving lamivudine monotherapy or combination therapy with lamivudine plus zidovudine, HIV-1 isolates from most patients became phenotypically and genotypically resistant to lamivudine within 12 weeks. In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of mutations conferring resistance to zidovudine.

Lamivudine-resistant HBV isolates develop substitutions (rtM204V/I) in the YMDD motif of the catalytic domain of the viral reverse transcriptase. rtM204V/I substitutions are frequently accompanied by other substitutions (rtV173L, rtL180M) which enhance the level of lamivudine resistance or act as compensatory mutations improving replication efficiency. Other substitutions detected in lamivudine-resistant HBV isolates include: rtL80I and rtA181T. Similar HBV mutants have been reported in HIV-1-infected patients who received lamivudine-containing antiretroviral regimens in the presence of concurrent infection with hepatitis B virus [see Warnings and Precautions (5.2)].

Tenofovir Disoproxil Fumarate: HIV-1 isolates with reduced susceptibility to tenofovir have been selected in cell culture. These viruses expressed a K65R substitution in reverse transcriptase and showed a 2 to 4 fold reduction in susceptibility to tenofovir.

In Study 903 of treatment-naïve subjects (tenofovir disoproxil fumarate + lamivudine + efavirenz versus stavudine + lamivudine + efavirenz) [See Clinical Studies (14.1)], genotypic analyses of isolates from subjects with virologic failure through Week 144 showed development of efavirenz and lamivudine resistance-associated substitutions to occur most frequently and with no difference between the treatment arms. The K65R substitution occurred in 8/47 (17%) analyzed patient isolates on the tenofovir disoproxil fumarate arm and in 2/49 (4%) analyzed patient isolates on the stavudine arm. Of the 8 subjects whose virus developed K65R in the tenofovir disoproxil fumarate arm through 144 weeks, 7 of these occurred in the first 48 weeks of treatment and one at Week 96. Other substitutions resulting in resistance to tenofovir disoproxil fumarate were not identified in this trial.

In Study 934 of treatment-naïve subjects (tenofovir disoproxil fumarate + emtricitabine + efavirenz versus zidovudine (AZT)/lamivudine (3TC) + efavirenz) [See Clinical Studies (14.1)], genotypic analysis performed on HIV-1 isolates from all confirmed virologic failure subjects with greater than 400 copies/mL of HIV-1 RNA at Week 144 or early discontinuation showed development of efavirenz resistance-associated substitutions occurred most frequently and was similar between the two treatment arms. The M184V substitution, associated with resistance to emtricitabine and lamivudine, was observed in 2/19 analyzed subject isolates in the tenofovir disoproxil fumarate + emtricitabine group and in 10/29 analyzed subject isolates in the zidovudine/lamivudine group. Through 144 weeks of Study 934, no subjects have developed a detectable K65R substitution in their HIV-1 as analyzed through standard genotypic analysis.

Cross-Resistance
Lamivudine: Lamivudine-resistant HIV-1 mutants were cross-resistant to didanosine (ddI) and zalcitabine (ddC). In some patients treated with zidovudine plus didanosine or zalcitabine, isolates resistant to multiple reverse transcriptase inhibitors, including lamivudine, have emerged.

Genotypic and Phenotypic Analysis of On-Therapy HIV-1 Isolates From Patients With Virologic Failure: Study EPV20001: Fifty-three of 554 (10%) patients enrolled in EPV20001 were identified as virological failures (plasma HIV-1 RNA level ≥400 copies/mL) by Week 48. Twenty-eight patients were randomized to the lamivudine once-daily treatment group and 25 to the lamivudine twice-daily treatment group. The median baseline plasma HIV-1 RNA levels of patients in the lamivudine once-daily group and lamivudine twice-daily group were 4.9 log_{10} copies/mL and 4.6 log_{10} copies/mL, respectively.

Genotypic analysis of on-therapy isolates from 22 patients identified as virologic failures in the lamivudine once-daily group showed that isolates from 0/22 patients contained treatment-emergent amino acid substitutions associated with zidovudine resistance (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E), isolates from 10/22 patients contained treatment-emergent amino acid substitutions associated with efavirenz resistance (L100I, K101E, K103N, V108I, or Y181C), and isolates from 8/22 patients contained a treatment-emergent lamivudine resistance-associated substitution (M184I or M184V).

Genotypic analysis of on-therapy isolates from patients (n = 22) in the lamivudine twice-daily treatment group showed that isolates from 1/22 patients contained treatment-emergent zidovudine resistance substitutions, isolates from 7/22 contained treatment-emergent efavirenz resistance substitutions, and isolates from 5/22 contained treatment-emergent lamivudine resistance substitutions.

Phenotypic analysis of baseline-matched on-therapy HIV-1 isolates from patients (n =13) receiving lamivudine once daily showed that isolates from 12/13 patients were susceptible to zidovudine; isolates from 8/13 patients exhibited a 25- to 295-fold decrease in susceptibility to efavirenz, and isolates from 7/13 patients showed an 85- to 299-fold decrease in susceptibility to lamivudine.

Phenotypic analysis of baseline-matched on-therapy HIV-1 isolates from patients (n = 13) receiving lamivudine twice daily showed that isolates from all 13 patients were susceptible to zidovudine; isolates from 3/13 patients exhibited a 21- to 342-fold decrease in susceptibility to efavirenz, and isolates from 4/13 patients exhibited a 29- to 159-fold decrease in susceptibility to lamivudine.

Study EPV40001: Fifty patients received zidovudine 300 mg twice daily plus abacavir 300 mg twice daily plus lamivudine 300 mg once daily and 50 patients received zidovudine 300 mg plus abacavir 300 mg plus lamivudine 150 mg all twice daily. The median baseline plasma HIV-1 RNA levels for patients in the 2 groups were 4.79 log_{10} copies/mL and 4.83 log_{10} copies/mL, respectively. Fourteen of 50 patients in the lamivudine once-daily treatment group and 9 of 50 patients in the lamivudine twice-daily group were identified as virologic failures.

Genotypic analysis of on-therapy HIV-1 isolates from patients (n = 9) in the lamivudine once-daily treatment group showed that isolates from 6 patients had an abacavir and/or lamivudine resistance-associated substitution M184V alone. On-therapy isolates from
patients (n = 6) receiving lamivudine twice daily showed that isolates from 2 patients had M184V alone, and isolates from 2 patients harbored the M184V substitution in combination with zidovudine resistance-associated amino acid substitutions.

Phenotypic analysis of on-therapy isolates from patients (n = 6) receiving lamivudine once daily showed that HIV-1 isolates from 4 patients exhibited a 32- to 53-fold decrease in susceptibility to lamivudine. HIV-1 isolates from these 6 patients were susceptible to zidovudine.

Phenotypic analysis of on-therapy isolates from patients (n = 4) receiving lamivudine twice daily showed that HIV-1 isolates from 1 patient exhibited a 45-fold decrease in susceptibility to lamivudine and a 4.5-fold decrease in susceptibility to zidovudine.

**Tenofovir Disoproxil Fumarate:** Cross-resistance among certain reverse transcriptase inhibitors has been recognized. The K65R substitution selected by tenofovir is also selected in some HIV-1 infected subjects treated with abacavir, didanosine, or zalcitabine. HIV-1 isolates with this mutation also show reduced susceptibility to emtricitabine and lamivudine. Therefore, cross-resistance among these drugs may occur in patients whose virus harbors the K65R substitution. HIV-1 isolates from subjects (N=20) whose HIV-1 expressed a mean of 3 zidovudine-associated reverse transcriptase substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility to tenofovir.

In Studies 902 and 907 conducted in treatment-experienced subjects (tenofovir disoproxil fumarate + Standard Background Therapy (SBT) compared to Placebo + SBT) [See Clinical Studies (14.1)], 14/304 (5%) of the tenofovir disoproxil fumarate-treated subjects with virologic failure through Week 96 had greater than 1.4-fold (median 2.7-fold) reduced susceptibility to tenofovir. Genotypic analysis of the baseline and failure isolates showed the development of the K65R substitution in the HIV-1 reverse transcriptase gene.

The virologic response to tenofovir disoproxil fumarate therapy has been evaluated with respect to baseline viral genotype (N=222) in treatment-experienced subjects participating in Studies 902 and 907. In these clinical trials, 94% of the participants evaluated had baseline HIV-1 isolates expressing at least one NRTI mutation. Virologic responses for subjects in the genotype substudy were similar to the overall trial results.

Several exploratory analyses were conducted to evaluate the effect of specific substitutions and substitutional patterns on virologic outcome. Because of the large number of potential comparisons, statistical testing was not conducted. Varying degrees of cross-resistance of tenofovir disoproxil fumarate to pre-existing zidovudine resistance-associated substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) were observed and appeared to depend on the type and number of specific substitutions. Tenofovir disoproxil fumarate-treated subjects whose HIV-1 expressed 3 or more zidovudine resistance-associated substitutions that included either the M41L or L210W reverse transcriptase substitution showed reduced responses to tenofovir disoproxil fumarate therapy; however, these responses were still improved compared with placebo. The presence of the D67N, K70R, T215Y/F, or K219Q/E/N substitution did not appear to affect responses to tenofovir disoproxil fumarate therapy. Subjects whose virus expressed an L74V substitution without zidovudine resistance associated substitutions (N=8) had reduced response to tenofovir disoproxil fumarate. Limited data are available for subjects whose virus expressed a Y115F substitution (N=3), Q151M substitution (N=2), or T69 insertion (N=4), all of whom had a reduced response.
In the protocol defined analyses, virologic response to tenofovir disoproxil fumarate was not reduced in subjects with HIV-1 that expressed the abacavir/emtricitabine/lamivudine resistance-associated M184V substitution. HIV-1 RNA responses among these subjects were durable through Week 48.

**Studies 902 and 907 Phenotypic Analyses**
Phenotypic analysis of baseline HIV-1 from treatment-experienced subjects (N=100) demonstrated a correlation between baseline susceptibility to tenofovir disoproxil fumarate and response to tenofovir disoproxil fumarate therapy. Table 15 summarizes the HIV-1 RNA response by baseline tenofovir disoproxil fumarate susceptibility.

**Table 15 HIV-1 RNA Response at Week 24 by Baseline Tenofovir Disoproxil Fumarate Susceptibility (Intent-To-Treat)**

<table>
<thead>
<tr>
<th>Baseline Tenofovir disoproxil fumarate Susceptibility</th>
<th>Change in HIV-1 RNA (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>-0.74 (35)</td>
</tr>
<tr>
<td>&gt;1 and ≤3</td>
<td>-0.56 (49)</td>
</tr>
<tr>
<td>&gt;3 and ≤4</td>
<td>-0.3 (7)</td>
</tr>
<tr>
<td>&gt;4</td>
<td>-0.12 (9)</td>
</tr>
</tbody>
</table>

a. Tenofovir susceptibility was determined by recombinant phenotypic Antivirogram assay (Virco).
b. Fold change in susceptibility from wild-type.
c. Average HIV-1 RNA change from baseline through Week 24 (DAVG_{24}) in log_{10} copies/mL.

**13 NONCLINICAL TOXICOLOGY**

**13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

*Lamivudine:* Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 10 times (mice) and 58 times (rats) those observed in humans at the recommended therapeutic dose for HIV-1 infection. Lamivudine was not active in a microbial mutagenicity screen or an in vitro cell transformation assay, but showed weak in vitro mutagenic activity in a cytogenetic assay using cultured human lymphocytes and in the mouse lymphoma assay. However, lamivudine showed no evidence of in vivo genotoxic activity in the rat at oral doses of up to 2,000 mg/kg, producing plasma levels of 35 to 45 times those in humans at the recommended dose for HIV-1 infection. In a study of reproductive performance, lamivudine administered to rats at doses up to 4,000 mg/kg/day, producing plasma levels 47 to 70 times those in humans, revealed no evidence of impaired fertility and no effect on the survival, growth, and development to weaning of the offspring.

*Tenofovir Disoproxil Fumarate:* Long-term oral carcinogenicity studies of tenofovir disoproxil fumarate in mice and rats were carried out at exposures up to approximately 16 times (mice) and 5 times (rats) those observed in humans at the therapeutic dose for HIV-1 infection. At the high dose in female mice, liver adenomas were increased at exposures 16 times that in humans. In rats, the study was negative for carcinogenic findings at exposures up to 5 times that observed in humans at the therapeutic dose.

Tenofovir Disoproxil Fumarate was mutagenic in the *in vitro* mouse lymphoma assay and negative in an *in vitro* bacterial mutagenicity test (Ames test). In an *in vivo* mouse micronucleus assay, tenofovir disoproxil fumarate was negative when administered to male
There were no effects on fertility, mating performance or early embryonic development when tenofovir disoproxil fumarate was administered to male rats at a dose equivalent to 10 times the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 15 days prior to mating through day seven of gestation. There was, however, an alteration of the estrous cycle in female rats.

13.2 Animal Toxicology and/or Pharmacology

Lamivudine
Reproduction studies have been performed in rats and rabbits at orally administered doses up to 4,000 mg/kg/day and 1,000 mg/kg/day, respectively, producing plasma levels up to approximately 35 times that for the adult HIV dose. No evidence of teratogenicity due to lamivudine was observed. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at exposure levels up to 35 times those in humans. Studies in pregnant rats and rabbits showed that lamivudine is transferred to the fetus through the placenta.

Tenofovir Disoproxil Fumarate
Tenofovir and Tenofovir Disoproxil Fumarate administered in toxicology studies to rats, dogs, and monkeys at exposures (based on AUCs) greater than or equal to 6 fold those observed in humans caused bone toxicity. In monkeys the bone toxicity was diagnosed as osteomalacia. Osteomalacia observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone toxicity is unknown.

Evidence of renal toxicity was noted in 4 animal species. Increases in serum creatinine, BUN, glycosuria, proteinuria, phosphaturia, and/or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2 to 20 times higher than those observed in humans. The relationship of the renal abnormalities, particularly the phosphaturia, to the bone toxicity is not known.

14 CLINICAL STUDIES

14.1 Clinical Efficacy in Patients with HIV-1 Infection

Treatment-Naïve Adult Patients

Study 903
Data through 144 weeks are reported for Study 903, a double-blind, active-controlled multicenter trial comparing tenofovir disoproxil fumarate (300 mg once daily) administered in combination with lamivudine and efavirenz versus stavudine (d4T), lamivudine, and efavirenz in 600 antiretroviral-naïve subjects. Subjects had a mean age of 36 years (range 18 to 64), 74% were male, 64% were Caucasian and 20% were Black. The mean baseline CD4+ cell count was 279 cells/mm³ (range 3 to 956) and median baseline plasma HIV-1 RNA was 77,600 copies/mL (range 417 to 5,130,000). Subjects were stratified by baseline HIV-1 RNA and CD4+ cell count. Forty-three percent of subjects had baseline viral loads >100,000 copies/mL and 39% had CD4+ cell counts <200 cells/mm³. Treatment outcomes through 48 and 144 weeks are presented in Table 16.

<table>
<thead>
<tr>
<th>Table 16 Outcomes of Randomized Treatment at Week 48 and 144 (Study 903)</th>
<th>At Week 48</th>
<th>At Week 144</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>Tenofovir disoproxil fumarate+3TC +EFV (N=299)</td>
<td>d4T+3TC C+EFV (N=301)</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Responder(^a)</td>
<td>79%</td>
<td>82%</td>
</tr>
<tr>
<td>Virologic failure(^b)</td>
<td>6%</td>
<td>4%</td>
</tr>
<tr>
<td>Rebound</td>
<td>5%</td>
<td>3%</td>
</tr>
<tr>
<td>Never suppressed</td>
<td>0%</td>
<td>1%</td>
</tr>
<tr>
<td>Added an antiretroviral agent</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>Death</td>
<td>&lt;1%</td>
<td>1%</td>
</tr>
<tr>
<td>Discontinued due to adverse event</td>
<td>6%</td>
<td>6%</td>
</tr>
<tr>
<td>Discontinued for other reasons(^c)</td>
<td>8%</td>
<td>7%</td>
</tr>
</tbody>
</table>

\(^a\) Subjects achieved and maintained confirmed HIV-1 RNA <400 copies/mL through Week 48 and 144.

\(^b\) Includes confirmed viral rebound and failure to achieve confirmed <400 copies/mL through Week 48 and 144.

\(^c\) Includes lost to follow-up, subject’s withdrawal, noncompliance, protocol violation and other reasons.

Achievement of plasma HIV-1 RNA concentrations of less than 400 copies/mL at Week 144 was similar between the two treatment groups for the population stratified at baseline on the basis of HIV-1 RNA concentration (> or \(\leq\) 100,000 copies/mL) and CD4\(^+\) cell count (< or \(\geq\) 200 cells/mm\(^3\)). Through 144 weeks of therapy, 62% and 58% of subjects in the tenofovir disoproxil fumarate and stavudine arms, respectively achieved and maintained confirmed HIV-1 RNA <50 copies/mL. The mean increase from baseline in CD4\(^+\) cell count was 263 cells/mm\(^3\) for the tenofovir disoproxil fumarate arm and 283 cells/mm\(^3\) for the stavudine arm. Through 144 weeks, 11 subjects in the tenofovir disoproxil fumarate group and 9 subjects in the stavudine group experienced a new CDC Class C event.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

Lamivudine and Tenofovir Disoproxil Fumarate Tablets (300/300mg) are supplied as capsule shaped bilayered, biconvex, film-coated tablets with one layer orange and other layer white in color, “LT” debossed on one side and plain on the other side. Each tablet contains 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate (which is equivalent to 245 mg of tenofovir disoproxil). Lamivudine and Tenofovir Disoproxil Fumarate Tablets (300/300mg) are packaged in white HDPE bottles with child resistance and non-child resistance closures with desiccant and a heat-sealed liner as follows:

- Bottles of 30 tablets
- Bottles of 500 tablets

Store at 25 \(^\circ\)C (77 \(^\circ\)F); excursions permitted to 15–30 \(^\circ\)C (59–86 \(^\circ\)F) [see USP Controlled Room Temperature].
- Keep container tightly closed.
- Dispense only in original container.
- Do not use if seal over bottle opening is broken or missing.

### 17 PATIENT COUNSELING INFORMATION
17.1 Information for Patients

Patients should be advised that:

- Lamivudine and Tenofovir Disoproxil Fumarate Tablets are not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician when using lamivudine and tenofovir disoproxil fumarate tablets.
- Patients should avoid doing things that can spread HIV or HBV to others.
  - Do not share needles or other injection equipment.
  - Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.
  - Do not have any kind of sex without protection. Always practice safe sex by using a latex or polyurethane condom or other barrier method to lower the chance of sexual contact with semen, vaginal secretions, or blood.
  - Do not breastfeed. Lamivudine is excreted in human breast milk. Mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.
- Patients should be informed to take all HIV medications exactly as prescribed.
- The long term effects of lamivudine and tenofovir disoproxil fumarate tablets are unknown.
- Lamivudine and tenofovir disoproxil fumarate tablets are for oral ingestion only.
- Lamivudine and Tenofovir Disoproxil Fumarate Tablets should not be discontinued without first informing their physician.
- If you have HIV-1 infection, with or without HBV coinfection, it is important to take lamivudine and tenofovir disoproxil fumarate tablets with combination therapy.
- It is important to take lamivudine and tenofovir disoproxil fumarate tablets on a regular dosing schedule and to avoid missing doses.
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Treatment with lamivudine and tenofovir disoproxil fumarate tablets should be suspended in any patient who develops clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort, and weakness) [See Warnings and Precautions (5.1)].
- Severe acute exacerbations of hepatitis have been reported in patients who are infected with HBV or coinfect with HBV and HIV-1 and have discontinued lamivudine and tenofovir disoproxil fumarate tablets. Patients should be advised to discuss any changes in regimen with their physician [See Warnings and Precautions (5.2)].
- Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported. Lamivudine and Tenofovir Disoproxil Fumarate Tablets should be avoided with concurrent or recent use of a nephrotoxic agent [See Warnings and Precautions (5.6)]. Lamivudine and tenofovir disoproxil fumarate tablets are not recommended for patients with impaired renal function (i.e., creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis [See Dosage and Administration (2.2)].
- Lamivudine and tenofovir disoproxil fumarate tablets should not be coadministered with other lamivudine-containing, tenofovir disoproxil fumarate-containing or emtricitabine-containing drugs, including EPIVIR (lamivudine), EPIVIR-HBV (lamivudine) Tablets, VIREAD (tenofovir disoproxil fumarate), COMBIVIR (lamivudine/zidovudine) Tablets, EPZICOM (abacavir sulfate and lamivudine) Tablets, TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine), EMTRIVA (emtricitabine), ATRIPLA (efavirenz, emtricitabine, and tenofovir), TRUVADA (emtricitabine and tenofovir) or COMPLERA (rilpivirine/emtricitabine/tenofovir) [See Warnings and Precautions (5.3)].
- Lamivudine and tenofovir disoproxil fumarate tablets should not be administered in...
combination with HEPESERA [See Warnings and Precautions (5.3)].

- Patients with HIV-1 should be tested for Hepatitis B virus (HBV) before initiating antiretroviral therapy [See Warnings and Precautions (5.2)].
- Decreases in bone mineral density have been observed with the use of lamivudine and tenofovir disoproxil fumarate tablets in patients with HIV. Bone mineral density monitoring should be considered in patients who have a history of pathologic bone fracture or at risk for osteopenia [See Warnings and Precautions (5.7)].
- Differences in Formulations of Lamivudine: Patients should be advised that Lamivudine tablet contain a higher dose of the same active ingredient (lamivudine) as EPIVIR-HBV Tablets and Oral Solution. If a decision is made to include lamivudine in the HIV-1 treatment regimen of a patient co-infected with HIV-1 and HBV, the formulation and dosage of lamivudine in Lamivudine (not EPIVIR-HBV) should be used [see Warnings and Precautions (5.2)].
- HIV-1/HCV Co-Infection: Patients with HIV-1/HCV co-infection should be informed that hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin [see Warnings and Precautions (5.4)].
- Risk of Pancreatitis: Parents or guardians should be advised to monitor pediatric patients for signs and symptoms of pancreatitis [see Warnings and Precautions (5.5)].
- Redistribution/Accumulation of Body Fat: Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including lamivudine and tenofovir disoproxil fumarate tablets, and that the cause and long-term health effects of these conditions are not known at this time [see Warnings and Precautions (5.9)].

Disclaimer:
Other brands (TRUVADA, ATRIPLA, TRIZIVIR®, COMBIVIR, EPZICOM, HEPESERA, VIREAD, EPIVIR) listed are the registered trademarks of their respective owners and are not of Cipla Ltd.
PATIENT INFORMATION

Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg

Read this Patient Information carefully before you start taking lamivudine and tenofovir disoproxil fumarate tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.

What is the most important information I should know about lamivudine and tenofovir disoproxil fumarate tablets?

Lamivudine and tenofovir disoproxil fumarate tablets can cause serious side effects, including:

1. **Build-up of an acid in your blood (lactic acidosis).** Lactic acidosis can happen in some people who take lamivudine, tenofovir disoproxil fumarate or similar (nucleoside analog) medicines. **Lactic acidosis** is a serious medical emergency that can lead to death.

   Lactic acidosis can be hard to identify early, because the symptoms could seem like symptoms of other health problems. **Call your healthcare provider right away if you get the following symptoms which could be signs of lactic acidosis:**
   - feeling very weak or tired
   - have unusual (not normal) muscle pain
   - have trouble breathing
   - have stomach pain with
     - nausea (feel sick to your stomach)
     - vomiting
   - feel cold, especially in your arms and legs
   - feel dizzy or lightheaded
   - have a fast or irregular heartbeat

2. **Severe liver problems.** Severe liver problems can happen in people who take lamivudine, tenofovir disoproxil fumarate or similar medicines. In some cases these liver problems can lead to death. Your liver may become large (hepatomegaly) and you may develop fat in your liver (steatosis) when you take lamivudine and tenofovir disoproxil fumarate tablets.

   **Call your healthcare provider right away if you have any of the following symptoms of liver problems:**
   - Your skin or the white part of your eyes turns yellow (jaundice).
   - dark “tea-colored” urine
   - light-colored bowl movements (stools)
   - loss of appetite for several days or longer
   - nausea
   - stomach pain

   You may be more likely to get lactic acidosis or severe liver problems if you are female, very overweight (obese), or have been taking lamivudine, tenofovir disoproxil fumarate or a similar medicine for a long time.

3. **Worsening of your Hepatitis B infection.** Your hepatitis B Virus (HBV) infection may become worse (flare-up) if you take tenofovir disoproxil fumarate and then stop it. A
“flare-up” is when your HBV infection suddenly returns in a worse way than before.

- Do not let your lamivudine and tenofovir disoproxil fumarate tablets run out. Refill your prescription or talk to your healthcare provider before your lamivudine and tenofovir disoproxil fumarate tablets is all gone.
- Do not stop taking lamivudine and tenofovir disoproxil fumarate tablets without first talking to your healthcare provider.
- If you stop taking lamivudine and tenofovir disoproxil fumarate tablets, your healthcare provider will need to check your health often and do blood tests regularly to check your HBV infection. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking lamivudine and tenofovir disoproxil fumarate tablets.

4. Talk to your doctor about taking an HBV test before starting treatment with lamivudine and tenofovir disoproxil fumarate tablets for treatment of HIV.

What are lamivudine and tenofovir disoproxil fumarate tablets?
Lamivudine and tenofovir disoproxil fumarate tablets are a prescription medicine used:
- with other antiviral medicines to treat Human Immunodeficiency Virus (HIV) in adults and pediatric patients 12 years of age and older and weighing at least 35 kg (77 lb). HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).
- When used with other HIV medicines, lamivudine and tenofovir disoproxil fumarate tablets may reduce the amount of HIV in your blood (called “viral load”). Lamivudine and tenofovir disoproxil fumarate tablets may also help to increase the number of CD4 (T) cells in your blood which help fight off other infections. Reducing the amount of HIV and increasing the CD4 (T) cell count may improve your immune system. This may reduce your risk of death or infections that can happen when your immune system is weak (opportunistic infections).
- Lamivudine and tenofovir disoproxil fumarate tablets do not cure HIV infection or AIDS. People taking lamivudine and tenofovir disoproxil fumarate tablets may still develop infections or other conditions associated with HIV infection.
- Patients must stay on continuous HIV therapy to control infection and decrease HIV-related illnesses.
- It is very important that you stay under the care of your healthcare provider.

What should I tell my healthcare provider before taking lamivudine and tenofovir disoproxil fumarate tablets?
Before you take lamivudine and tenofovir disoproxil fumarate tablets, tell your healthcare provider if you:
- have liver problems, including hepatitis B (HBV) infection
- have kidney problems
- have bone problems
- have any other medical conditions, including HIV infection
- are pregnant or plan to become pregnant. It is not known if lamivudine and tenofovir disoproxil fumarate tablets will harm your unborn baby.

Do not breastfeeding if you are taking lamivudine and tenofovir disoproxil fumarate tablets. Tenofovir passes into your breast milk. You should not breastfeed because of the risk of passing HIV to your baby. Talk to your healthcare provider about the best way to feed your baby.

Tell your healthcare provider about all the medicines you take, including prescription and
non-prescription medicines, vitamins and herbal supplements. Lamivudine and tenofovir disoproxil fumarate tablets may affect the way other medicines work, and other medicines may affect how lamivudine and tenofovir disoproxil fumarate tablets work.

Do not take lamivudine and tenofovir disoproxil fumarate tablets if you also take:
- other medicines that contain tenofovir (ATRIPLA, COMPLERA, TRUVADA)
- other medicines that contain lamivudine or emtricitabine (EPIVIR, EPIVIR-HBV, COMBIVIR, EPZICOM, TRIZIVIR, EMTRIVA)
- adefovir (HEPSERA)

Especially tell your healthcare provider if you take the following medications, as the dose of these other medications may need to be changed:
- didanosine (VIDEX, VIDEX EC)
- atazanavir (REYATAZ)
- lopinavir with ritonavir (KALETRA)

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take lamivudine and tenofovir disoproxil fumarate tablets?
- See “What is the most important information I should know about lamivudine and tenofovir disoproxil fumarate tablets”?
- Take lamivudine and tenofovir disoproxil fumarate tablets exactly as your healthcare provider tells you to take them.
- Take lamivudine and tenofovir disoproxil fumarate tablets at the same time every day.
- The usual dose of lamivudine and tenofovir disoproxil fumarate tablets is 1 tablet each day. If you are an adult and have kidney problems, your healthcare provider may tell you not to take lamivudine and tenofovir disoproxil fumarate tablets.
- Take lamivudine and tenofovir disoproxil fumarate tablets by mouth on an empty stomach.
- Do not miss a dose of lamivudine and tenofovir disoproxil fumarate tablets. If you miss a dose of lamivudine and tenofovir disoproxil fumarate tablets, take the missed dose as soon as you remember. If it is almost time for your next dose of lamivudine and tenofovir disoproxil fumarate tablets, do not take the missed dose. Take the next dose of lamivudine and tenofovir disoproxil fumarate tablets at your regular time.
- If you take too much lamivudine and tenofovir disoproxil fumarate tablets, call your local poison control center or go right away to the nearest hospital emergency room.

What are the possible side effects of lamivudine and tenofovir disoproxil fumarate tablets?
Lamivudine and tenofovir disoproxil fumarate tablets may cause serious side effects, including:
- See “What is the most important information I should know about lamivudine and tenofovir disoproxil fumarate tablets”?
- New or worse kidney problems can happen in some people who take lamivudine and tenofovir disoproxil fumarate tablets. If you have had kidney problems in the past or need to take another medicine that can cause kidney problems, your healthcare provider may need to do blood tests to check your kidneys during your treatment with lamivudine and tenofovir disoproxil fumarate tablets.
- Bone problems can happen in some people who take lamivudine and tenofovir disoproxil fumarate tablets. Bone problems include bone pain, softening or thinning (which may
lead to fractures). Your healthcare provider may need to do additional tests to check your bones.

- **Changes in body fat** can happen in some people who take antiviral medicines. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breast, and around the main part of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known.

- **Changes in your immune system (Immune Reconstitution Syndrome)** can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider if you start having new symptoms after starting your HIV medicine.

The most common side effects in all people who take lamivudine and tenofovir disoproxil fumarate tablets are:

- nausea
- rash
- diarrhea
- headache
- pain
- depression
- weakness
- fatigue
- nasal signs and symptoms
- cough

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of lamivudine and tenofovir disoproxil fumarate tablets. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How do I store lamivudine and tenofovir disoproxil fumarate tablets?**

- Store lamivudine and tenofovir disoproxil fumarate tablets at room temperature 77°F (25°C). It should remain stable until the expiration date printed on the label.
- Do not keep your medicine in places that are too hot or cold.
- Do not keep medicine that is out of date or that you no longer need. If you throw any medicines away make sure that children will not find them.
- Keep lamivudine and tenofovir disoproxil fumarate tablets in the original container.
- Do not use lamivudine and tenofovir disoproxil fumarate tablets if the seal over the bottle opening is broken or missing.
- Keep the bottle tightly closed.

**Keep lamivudine and tenofovir disoproxil fumarate tablets and all medicines out of the reach of children.**

**General information about lamivudine and tenofovir disoproxil fumarate tablets:**
Medicines are sometimes prescribed for purposes other than those listed in the patient leaflet.
Do not use lamivudine and tenofovir disoproxil fumarate tablets for a condition for which it was not prescribed. Do not give lamivudine and tenofovir disoproxil fumarate tablets to other people, even if they have the same condition you have. It may harm them.

Avoid doing things that can spread HIV-1 or HBV infection to others.
- Do not share needles or other injection equipment.
- Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.
- Do not have any kind of sex without protection. Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.

This leaflet summarizes the most important information about lamivudine and tenofovir disoproxil fumarate tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about lamivudine and tenofovir disoproxil fumarate that is written for health professionals.

For more information, go to www.cipla.com or call Cipla Ltd. at 1-866-604-3268.

What are the ingredients in lamivudine and tenofovir disoproxil fumarate tablets?
Active Ingredients: Lamivudine and Tenofovir Disoproxil Fumarate

Inactive Ingredients: Microcrystalline Cellulose, Lactose Monohydrate, Sodium Starch Glycolate, Corn Starch, Croscarmellose Sodium, Magnesium Stearate, Polysorbate 80, FD&C Yellow No 6 (Aluminium Lake), Opadry AMBOY-B-29000 Translucent (Polyvinyl alcohol- Part. Hydrolyzed, Talc, Lecithin (soya), Xanthan Gum).

Rx Only
Dated: August 2012

The brands listed are trademarks of their respective owners and are not trademarks of Cipla Ltd.

Cipla Ltd.
Mumbai Central,
Mumbai,
India